Skip to main content
PLOS Pathogens logoLink to PLOS Pathogens
. 2022 Mar 23;18(3):e1010398. doi: 10.1371/journal.ppat.1010398

A CRISPR-Cas9 screen reveals a role for WD repeat-containing protein 81 (WDR81) in the entry of late penetrating viruses

Anthony J Snyder 1, Andrew T Abad 1, Pranav Danthi 1,*
Editor: Christiane E Wobus2
PMCID: PMC8942271  PMID: 35320319

Abstract

Successful initiation of infection by many different viruses requires their uptake into the endosomal compartment. While some viruses exit this compartment early, others must reach the degradative, acidic environment of the late endosome. Mammalian orthoreovirus (reovirus) is one such late penetrating virus. To identify host factors that are important for reovirus infection, we performed a CRISPR-Cas9 knockout (KO) screen that targets over 20,000 genes in fibroblasts derived from the embryos of C57/BL6 mice. We identified seven genes (WDR81, WDR91, RAB7, CCZ1, CTSL, GNPTAB, and SLC35A1) that were required for the induction of cell death by reovirus. Notably, CRISPR-mediated KO of WD repeat-containing protein 81 (WDR81) rendered cells resistant to reovirus infection. Susceptibility to reovirus infection was restored by complementing KO cells with human WDR81. Although the absence of WDR81 did not affect viral attachment efficiency or uptake into the endosomal compartments for initial disassembly, it reduced viral gene expression and diminished infectious virus production. Consistent with the role of WDR81 in impacting the maturation of endosomes, WDR81-deficiency led to the accumulation of reovirus particles in dead-end compartments. Though WDR81 was dispensable for infection by VSV (vesicular stomatitis virus), which exits the endosomal system at an early stage, it was required for VSV-EBO GP (VSV that expresses the Ebolavirus glycoprotein), which must reach the late endosome to initiate infection. These results reveal a previously unappreciated role for WDR81 in promoting the replication of viruses that transit through late endosomes.

Author summary

Viruses are obligate intracellular parasites that require the contributions of numerous host factors to complete the viral life cycle. Thus, the host-pathogen interaction can regulate cell death signaling and virus entry, replication, assembly, and egress. Functional genetic screens are useful tools to identify host factors that are important for establishing infection. Such information can also be used to understand cell biology. Notably, genome-scale CRISPR-Cas9 knockout screens are robust due to their specificity and the loss of host gene expression. Mammalian orthoreovirus (reovirus) is a tractable model system to investigate the pathogenesis of neurotropic and cardiotropic viruses. Using a CRISPR-Cas9 screen, we identified WD repeat-containing protein 81 (WDR81) as a host factor required for efficient reovirus infection of murine cells. Ablation of WDR81 blocked a late step in the viral entry pathway. Further, our work indicates that WDR81 is required for the entry of vesicular stomatitis virus that expresses the Ebolavirus glycoprotein.

Introduction

As obligate intracellular parasites, viruses are dependent on host factors for many stages of virus replication. Classically, these factors were identified individually using biochemical methods and then biologically validated. More recently, functional genetic screens have been performed using genome-wide siRNA libraries, insertional mutagenesis of haploid cell lines, and CRISPR-Cas9 knockout screens [13]. Among these, CRISPR-Cas9 screening methods are likely the most robust because they are highly specific and typically result in the complete loss of gene expression due to genetic ablation. Curiously, however, screens for proviral host factors against the same virus in different cell lines can result in the identification of distinct host factors [4,5]. Such results indicate that while a subset of host factors is required to support replication of the virus in all cell types, the relative importance of other host factors for replication in different cell types varies. These results suggest that screens performed under different conditions are likely to reveal new host dependency factors.

Mammalian orthoreovirus (reovirus) is a segmented double-stranded RNA (dsRNA) virus with two concentric, protein shells [6]. Reovirus is used as a tractable model to investigate the pathogenesis of neurotropic and cardiotropic viruses. Multiple host and viral determinants that influence reovirus replication and host responses in human or murine cell lines also influence reovirus pathogenesis in a newborn mouse model [711]. As such, a number of proviral host factors have been identified for reovirus. These include cell surface molecules, such as cell surface glycans [12,13], Junctional adhesion molecule A (JAM-A) [14], Nogo Receptor 1 (NgR1) [15], and β1 integrin [16, 17], that directly engage reovirus particles. The steps following reovirus attachment are also dependent on host factors that deliver reovirus particles to late endosomes [1822]. Within endosomes, low pH-dependent cathepsin B and L proteases mediate disassembly of the particle to generate an entry intermediate called infectious subvirion particle (ISVP) [23]. ISVPs undergo conformational transitions to form ISVP*s and deliver the genome-containing core particle (inner shell) into the host cytoplasm [24]. Cores transcribe viral mRNA that is translated and packaged into progeny cores generated from viral proteins. Following intraparticle dsRNA synthesis, the outer shell proteins are assembled onto the particle for subsequent release from infected cells. Surprisingly, with the exception of the TRiC chaperonin complex, which aids in reovirus outer shell assembly [25,26], few other host factors that act after ISVP formation have been identified.

In this work, we report the identification of host factors that are required for the infection of mouse embryo fibroblasts by reovirus using a CRISPR-Cas9 knockout screen. Among these, we find the BEACH (beige and Chediak–Higashi) and WD40 repeat-containing protein, WDR81, is required. WDR81 is a cytoplasmic protein that localizes with Early Endosome Antigen 1 (EEA1) and Lysosomal Associated Membrane Protein 1

(LAMP1) positive endolysosomal compartments [27,28]. WDR81 controls endosomal maturation by modulating phosphatidylinositol 3-phosphate (PtdIns3P) levels [28]. In the absence of WDR81, the transport of cargo destined for lysosomal enzyme mediated degradation is inhibited [27,28]. We find that in WDR81-deficient cells, native reovirus particles are endocytosed and converted to ISVPs but fail to initiate further replication. Thus, WDR81 is required for the functional entry of ISVPs, which are generated in endosomes. Additionally, using vesicular stomatitis virus (VSV) and VSV that expresses the Ebolavirus glycoprotein (VSV-EBO GP), we find a role for WDR81 in the entry of other viruses that pass through the late endosome.

Materials and methods

Cells and viruses

Murine L929 (L) cells were grown at 37°C in Joklik’s Minimal Essential Medium (Lonza) supplemented with 5% fetal bovine serum (FBS) (Life Technologies), 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin (Invitrogen), 100 μg/ml streptomycin (Invitrogen), and 25 ng/ml amphotericin B (Sigma-Aldrich). C57/BL6-derived mouse embryo fibroblasts (MEFs) (American Type Culture Collection) were grown at 37°C in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% FBS (Life Technologies) and 2 mM L-glutamine (Invitrogen). Baby Hamster Kidney-21 (BHK-21) cells (American Type Culture Collection) were grown at 37°C in Minimal Essential Medium (Mediatech) supplemented with 10% FBS (Life Technologies), nonessential amino acids (Gibco), 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin (Invitrogen), and 100 μg/ml streptomycin (Invitrogen). Human embryonic kidney (HEK) 293 FT cells (Thermo Fisher Scientific) were grown at 37°C in DMEM (Gibco) supplemented with GlutaMAX (Gibco) and 10% FBS (Life Technologies). All reovirus experiments were performed with Type 3 Dearing from the Cashdollar laboratory (T3DCD), which was provided by Dr. John Parker (Cornell University) [29], or with Type 1 Lang (T1L), which was generated by plasmid-based reverse genetics [30]. Vesicular stomatitis virus (VSV [GFP]) and Ebola Virus (EBO) glycoprotein (GP) expressing VSV (VSV-EBO GP [GFP]) were provided by Dr. Sean Whelan (Washington University School of Medicine in St. Louis). VSV (GFP) and VSV-EBO GP (GFP) were engineered to express green fluorescent protein (GFP) within infected cells [31].

Reovirus propagation purification

Reovirus T3DCD and T1L were propagated and purified as previously described [32]. Briefly, L cells infected with second passage reovirus stocks were lysed by sonication. Virions were extracted from lysates using Vertrel-XF specialty fluid (Dupont). The extracted particles were layered onto 1.2- to 1.4-g/cm3 CsCl step gradients. The gradients were then centrifuged at 187,000×g for 4 h at 4°C. Bands corresponding to purified virions (~1.36 g/cm3) [33] were isolated and dialyzed into virus storage buffer (10 mM Tris-HCl, pH 7.4, 15 mM MgCl2, and 150 mM NaCl). Following dialysis, the particle concentration was determined by measuring the optical density of the purified virion stocks at 260 nm (OD260; 1 unit at OD260 = 2.1×1012 particles/ml) [33]. The purification of virions was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie brilliant blue (Sigma-Aldrich) staining.

Generation of reovirus infectious subviral particles (ISVPs)

Unlabeled and Alexa Fluor 488 (AF488)-labeled T3DCD or T1L virions (2×1012 particles/ml) were digested with 200 μg/ml Nα-p-tosyl-L-lysine chloromethyl ketone (TLCK)-treated chymotrypsin (Worthington Biochemical) in a total volume of 100 μl for 20 min at 32°C [34]. The reactions were then incubated on ice for 20 min and quenched by the addition of 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich). The generation of ISVPs was confirmed by SDS-PAGE and Coomassie brilliant blue (Sigma-Aldrich) staining.

VSV (GFP) and VSV-EBO GP (GFP) propagation

BHK-21 cells were adsorbed with stocks of VSV (GFP) or VSV-EBO GP (GFP) at 5 PFUs/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium for 24 h at 37°C. Cell medium containing VSV (GFP) or VSV-EBO GP (GFP) was isolated and stored at -80°C.

Dynamic light scattering

Unlabeled and AF488-labeled T3DCD (2×1012 particles/ml) were analyzed using a Zetasizer Nano S dynamic light scattering system (Malvern Instruments). All measurements were made at room temperature in a quartz Suprasil cuvette with a 3.00-mm-path length (Hellma Analytics). For each sample, the size distribution profile was determined by averaging readings across 15 iterations.

Reovirus plaque assays

Plaque assays to determine infectivity were performed [35]. Briefly, virions, ISVPs, or infected cell lysates were diluted into phosphate buffered saline (PBS) supplemented with 2 mM MgCl2 (PBSMg). L cells grown in 6-well plates (Greiner Bio-One) were infected with 250 μl of the diluted virus for 1 h at room temperature. Following the viral attachment incubation, the monolayers were overlaid with 4 ml of serum-free medium 199 (Sigma-Aldrich) supplemented with 1% Bacto Agar (BD Biosciences), 10 μg/ml TLCK-treated chymotrypsin (Worthington, Biochemical), 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin (Invitrogen), 100 μg/ml streptomycin (Invitrogen), and 25 ng/ml amphotericin B (Sigma-Aldrich). The infected cells were incubated at 37°C, and plaques were counted at 5 days post infection.

VSV (GFP) and VSV-EBO GP (GFP) plaque assays

Cell medium containing VSV (GFP) or VSV-EBO GP (GFP) was diluted into PBSMg. BHK-21 cells grown in 6-well plates (Greiner Bio-One) were infected with 250 μl of the diluted virus for 1 h at room temperature. Following the viral attachment incubation, the monolayers were overlaid with 2 ml of Minimal Essential Medium (Mediatech) supplemented with 5% FBS (Life Technologies), nonessential amino acids (Gibco), 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin (Invitrogen), 100 μg/ml streptomycin (Invitrogen), and 1% low melt agarose (Fisher Scientific). The infected cells were incubated at 37°C, and plaques were counted at 2 days post infection.

Genome-scale CRISPR-Cas9 screen

The genome-scale CRISPR-Cas9 screen was performed using the mouse GeCKOv2 sgRNA library (Fig 1A) (Addgene) [36]. Briefly, lentivirus that harbored the mouse GeCKOv2 sgRNA library in the lentiCRISPRv2 vector (Addgene) was produced in HEK293FT cells (Thermo Fisher Scientific). MEF cells grown in 150-mm dishes (Greiner Bio-One) were transduced with the sgRNA library lentivirus at 0.3 infectious units/cell diluted in 8 μg/ml polybrene (EMD Millipore) [36], and the transduced cells were selected with 2 μg/ml puromycin (InvivoGen) in growth medium for 5 days at 37°C. The cells were plated for full coverage of the library (pools A and B) [36]. The transduced and puromycin-resistant cells were then adsorbed with T3DCD at 5 plaque forming units (PFUs)/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium for 7 d at 37°C. After 7 d, the virus-resistant cell population was transferred to fresh 150-mm dishes (Greiner Bio-One) and allowed to expand in growth medium supplemented with 2 μg/ml puromycin (InvivoGen) for 1–2 d at 37°C. Following expansion, the genomic DNA (gDNA) was prepared using the Quick-DNA Midiprep Plus Kit (Zymo Research), and the integrated sgRNAs were amplified by polymerase chain reaction (PCR) [36]. The PCR products were isolated by agarose gel electrophoresis and subsequent gel extraction using the QIAquick Gel Extraction Kit (Qiagen). The purified PCR products were then processed and sequenced using the NextSeq 75 –High Output (82 cycles in read 1, 8 cycles in index 1, and 8 cycles in index 2 SE reads) (Illumina). The sequencing data was analyzed using the Model-Based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) system [37].

Fig 1. Genome-scale CRISPR-Cas9 knockout screen.

Fig 1

(A) Strategy and workflow to identify host factors that are important for reovirus infection. (B and C) Screen results for gene-targeting sgRNAs that were enriched in the virus-resistant cell population. WDR81 sgRNA sequences were highly represented in the recovered clones (n = 2 biological replicates). (D and E) Genomic DNA and protein sequences for CTSL- (D) and WDR81- (E) deficient cell lines. The CTSL- and WDR81-targeting sgRNA sequences are bolded in red and blue, respectively.

Generation of CRISPR modified cell lines

Non-targeting (NT), Cathepsin L (CTSL), and WD repeat-containing protein 81 (WDR81) variant cell lines were generated using CRISPR technology. Briefly, the sgRNA sequences representing NT, CTSL, and WDR81 targets were cloned into the lentiCRISPRv2 vector (Addgene) using Golden Gate assembly reactions [36]. The primers used for cloning were as follows: NT ([5’-CACCGCTGAAAAAGGAAGGAGTTGA-3’] and [5’-AAACTCAACTCCTTCCTTTTTCAGC-3’]), CTSL ([5’-CACCGCATTACCTGAACTATAGAAC-3’] and [5’-AAACGTTCTATAGTTCAGGTAATGC-3’]), and WDR81([5’-CACCGCAGCCGACTGAACAGCCGCA-3’] and [5’-AAACTGCGGCTGTTCAGTCGGCTGC-3’]). Lentivirus that harbored the NT, CTSL, or WDR81 sgRNA in the lentiCRISPRv2 vector (Addgene) was produced in HEK293FT cells (Thermo Fisher Scientific). MEF cells grown in 6-well plates (Greiner Bio-One) were transduced with the lentivirus at 0.3 infectious units/cell diluted in 8 μg/ml polybrene (EMD Millipore) as previously described, and the transduced cells were selected with 2 μg/ml puromycin (InvivoGen) in growth medium for 5 days at 37°C. The transduced and puromycin-resistant cells were then transferred to 150-mm dishes (Greiner Bio-One) by limiting-dilution and allowed to expand in growth medium supplemented with 2 μg/ml puromycin (InvivoGen) for 3–5 d at 37°C. Single colonies were isolated using glass cloning cylinders (Sigma-Aldrich), transferred to 6-well plates (Greiner Bio-One), and allowed to expand in growth medium supplemented with 2 μg/ml puromycin (InvivoGen) for 3–5 d at 37°C. To identify and validate isolates that contain a modified CTSL or WDR81, gDNA was prepared using the Quick-DNA Midiprep Plus Kit (Zymo Research), and the gene encoding regions were amplified by PCR. The primers used for amplification were as follows: CTSL ([5’-GGACATAGTGTCCATAAGTCCTC-3’] and [5’-CTTCCGTGGGATTCTCATTTCCTC-3’]) and WDR81([5’-GTAGGAAGACCACAGATTCAGTG-3’] and [5’-CCAGCTGAGTGATAAGAGCAGTAC-3’]). The PCR products were isolated by agarose gel electrophoresis and subsequent gel extraction using the QIAquick Gel Extraction Kit (Qiagen). The purified PCR products then were processed and sequenced. The primers used for sequencing were as follows: CTSL ([5’-GGTTCCAGAACCCATATTAGACAG-3’] and [5’-GAGTTCGCTGTGGCTAATGACAC-3’]) and WDR81([5’-CAAGACCTCGTGGCTAATGC-3’] and [5’-CCACATTGCCTACCTGTATGGAG-3’]).

Generation of WDR81 complementing cell lines

NT-empty, ΔWDR81-empty, and ΔWDR81-WDR81 cells were generated using a lentivirus transduction and selection strategy. Briefly, the lentiviral vectors pHRSIN.pSFFV MCS(+) pSV40 Blast and pHRSIN.pSFFV 2xHA-WDR81 pSV40 Blast, which encode empty and human WDR81 fused to two hemagglutinin (HA) tags, respectively, were provided by Dr. Paul Lehner (University of Cambridge) [27]. These vectors were used to produce lentivirus in HEK293FT cells (Thermo Fisher Scientific). NT and ΔWDR81 cells grown in 6-well plates (Greiner Bio-One) were transduced with the lentiviruses at 0.3 infectious units/cell diluted in 8 μg/ml polybrene (EMD Millipore) as previously described, and the transduced cells were selected with 2 μg/ml puromycin (InvivoGen) and 8 μg/ml blasticidin (InvivoGen) in growth medium for 5 days at 37°C. The transduced and puromycin- and blasticidin-resistant cells were then transferred to 150-mm dishes (Greiner Bio-One) by limiting-dilution and allowed to expand in growth medium supplemented with 2 μg/ml puromycin (InvivoGen) and 8 μg/ml blasticidin (InvivoGen) for 3–5 d at 37°C. Single colonies were isolated using glass cloning cylinders (Sigma-Aldrich), transferred to 6-well plates (Greiner Bio-One), and allowed to expand in growth medium supplemented with 2 μg/ml puromycin (InvivoGen) and 8 μg/ml blasticidin (InvivoGen) for 3–5 d at 37°C. To identify and validate isolates that express 2xHA-WDR81, NT-empty, ΔWDR81-empty, and ΔWDR81-WDR81 cells were grown in 96-well plates (Greiner Bio-One). At ~90% confluency, the cells were fixed with 100 μl of methanol for 30 min at -20°C, washed three times with PBS, and blocked with PBS supplemented with 2.5% BSA and 0.25% Triton X-100 (TX-100) for 30 min at room temperature. The blocked cells were incubated with an α-HA-biotin primary antibody (Sigma-Aldrich) diluted 1:1,000 into PBS supplemented with 0.25% TX-100 for 30 min at 37°C. The cells were washed three times with PBS followed by incubation with an IRDye 800CW Streptavidin secondary antibody (LI-COR) diluted 1:5,000 into PBS supplemented with 0.25% TX-100 for 30 min at 37°C. The cells were then washed three times with PBS and total cells were labeled with a 1:1,000 dilution of DRAQ5 (Cell Signaling Technology) for 5 min at 4°C. The cells were washed three times with PBS and scanned using an Odyssey imaging system (LI-COR).

Sequence analysis

The reference sequences for Mus musculus (house mouse) derived CTSL and WDR81 and for Homo sapiens (human) derived WDR81 were obtained from the National Center for Biotechnology Information database.

Assessment of reovirus-induced cell death

NT, ΔCTSL, ΔWDR81, NT-empty, ΔWDR81-empty, and ΔWDR81-WDR81 cells were grown in 96-well plates (Greiner Bio-One). The cells were adsorbed with T3DCD at 5 PFUs/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium for 24 or 48 h at 37°C. Cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) by following the manufacturer’s instructions. Relative cell viability was calculated by dividing the luminescent values of infected cells by the luminescent values of uninfected cells.

Assessment of VSV (GFP)- and VSV-EBO GP (GFP)-induced cell death

NT, ΔCTSL, and ΔWDR81 cells were grown in 96-well plates (Greiner Bio-One). The cells were adsorbed with VSV (GFP) or VSV-EBO GP (GFP) at 5 PFUs/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium for 18 or 26 h at 37°C. Cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) following the manufacturer’s instructions. Relative cell viability was calculated by dividing the luminescent values of infected cells by the luminescent values of uninfected cells.

Assessment of reovirus cell attachment by indirect immunofluorescence

Quantification of reovirus attachment was performed as previously described [38]. Briefly, NT, ΔCTSL, and ΔWDR81 cells grown in 96-well plates (Greiner Bio-One) were chilled for 15 min at 4°C. The chilled cells were adsorbed with T3DCD at 1.0×106 virions/cell or 1.0×106 ISVPs/cell for 1 h at 4°C. After 1 h, the cells were washed three times with chilled PBS and blocked with PBS supplemented with 5% bovine serum albumin (PBS-BSA) for 10 min at 4°C. The cells were then incubated with an α-reovirus primary antibody [39] diluted 1:2,500 into PBS-BSA for 30 min at 4°C. The cells were washed three times with PBS-BSA followed by incubation with an IRDye 800CW secondary antibody (LI-COR) diluted 1:1,000 into PBS-BSA for 30 min at 4°C. After two washes with PBS-BSA, total cells were labeled with a 1:1,000 dilution of DRAQ5 (Cell Signaling Technology) for 5 min at 4°C. The cells were washed three times with PBS-BSA and then fixed with 4% formaldehyde for 20 min at room temperature. The fixed plates were scanned using an Odyssey imaging system (LI-COR). The binding index was quantified by the ratio of green (attached virus) and red (total cells) fluorescence using Image Studio Lite software (LI-COR).

Assessment of reovirus in-cell particle disassembly

NT, ΔCTSL, and ΔWDR81 cells grown in 24-well plates (Greiner Bio-One) were chilled for 15 min at 4°C. The chilled cells were adsorbed with T3DCD at 1.0×103 virions/cell for 1 h at 4°C. After 1 h, the cells were washed three times with PBS and incubated in growth medium at 37°C. At the indicated times post infection, the infected monolayers were washed three times with PBS and lysed with RIPA buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1% Triton X-100, 1% DOC, 0.1% SDS, and 1 mM EDTA). The cell lysates were solubilized in reducing SDS sample buffer and analyzed by SDS-PAGE. The levels of reovirus μ1C/δ and the PSTAIR epitope of the host protein Cdk1 were determined by Western blot using an anti-reovirus primary antibody and an anti-PSTAIR primary antibody (Sigma-Aldrich), respectively.

Assessment of reovirus infectivity by RNA transcription

NT, ΔCTSL, and ΔWDR81 cells were grown in 6-well plates (Greiner Bio-One). The cells were adsorbed with T3DCD at 5 PFUs/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium for 6 or 18 h at 37°C. The cells were then washed three times with PBS and lysed with Tri Reagent (Molecular Research Center). Total RNA was extracted from the cell lysates by following the manufacturer’s instructions. For quantitative reverse transcription-PCR (qRT-PCR), 1 μg of RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems) following the manufacturer’s instructions and gene specific primers against the T3DCD S1 gene segment ([5’-TGGCGAGATTATTCCCTGAC-3’]) and the murine glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA ([5’-GGATGCAGGGATGATGTTCT-3’]). The cDNA was diluted 1:10 into ultrapure H2O, mixed with forward and reverse detection primers (T3DCD S1 forward [5’-TACGCGTTGATCACGACAAT-3’] and T3DCD S1 reverse [5’-TGGCGAGATTATTCCCTGAC-3’] or GAPDH forward [5’-ACCCAGAAGACTGTGGATGG-3’] and GAPDH reverse [5’-GGATGCAGGGATGATGTTCT-3’]) and SYBR Select Master Mix (Applied Biosystems), and then subjected to PCR using the StepOnePlus Real-Time PCR system (Applied Biosystems). Multiple qRT-PCR measurements were made for each sample. ΔCT values were calculated by subtracting the threshold cycle (CT) values of GAPDH from the CT values of the T3DCD S1 gene segment. Levels of RNA transcription with respect to the control sample was quantified using the ΔΔCT method [40].

Assessment of reovirus infectivity by initiation of protein synthesis

NT, ΔCTSL, and ΔWDR81 cells were grown in 24-well plates (Greiner Bio-One). The cells were adsorbed with T3DCD at 5 PFUs/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium at 37°C. At the indicated times post infection, the infected monolayers were washed three times with PBS and lysed with RIPA buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1% Triton X-100, 1% DOC, 0.1% SDS, and 1 mM EDTA). The cell lysates were solubilized in reducing SDS sample buffer and analyzed by SDS-PAGE. The levels of reovirus σNS and the PSTAIR epitope of the host protein CDK1 were determined by Western blot using an anti-σNS primary antibody [41] and an anti-PSTAIR primary antibody (Sigma-Aldrich), respectively.

Assessment of VSV (GFP) and VSV-EBO GP (GFP) infectivity by initiation of protein synthesis

NT, ΔCTSL, and ΔWDR81 cells were grown in 6-well plates (Greiner Bio-One). The cells were adsorbed with VSV (GFP) or VSV-EBO GP (GFP) at 5 PFUs/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium at 37°C in an IncuCyte S3 Live-Cell Analysis System (Sartorius). At the indicated times post infection, three images per well were acquired using a X10 objective and green (excitation [440–480 nm], emission [504–544 nm]) and phase channels. The images were analyzed using the IncuCyte S3 Live-Cell Analysis System (Sartorius) software and plotted as GFP positive cells (per image) / Percent cell confluency versus Time post infection (h).

Assessment of reovirus infectivity by indirect immunofluorescence

NT, ΔCTSL, ΔWDR81, NT-empty, ΔWDR81-empty, and ΔWDR81-WDR81 cells were grown in 96-well plates (Greiner Bio-One). The cells were adsorbed with T3DCD at 5 PFUs/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium for 18 h at 37°C. The infected monolayers were fixed with 100 μl of methanol for 30 min at -20°C, washed three times with PBS, and blocked with PBS supplemented with 2.5% BSA and 0.25% Triton X-100 (TX-100) for 30 min at room temperature. The blocked cells were incubated with an α-reovirus primary antibody diluted 1:5,000 into PBS supplemented with 0.25% TX-100 for 30 min at 37°C. The cells were washed three times with PBS followed by incubation with an IRDye 800CW secondary antibody (LI-COR) diluted 1:5,000 into PBS supplemented with 0.25% TX-100 for 30 min at 37°C. The cells were then washed three times with PBS and total cells were labeled with a 1:1,000 dilution of DRAQ5 (Cell Signaling Technology) for 5 min at 4°C. The cells were washed three times with PBS and scanned using an Odyssey imaging system (LI-COR). Infectivity index was quantified by the ratio of green (virus infected cells) and red (total cells) fluorescence using Image Studio Lite software (LI-COR).

Single step reovirus growth assay

NT, ΔCTSL, ΔWDR81, NT-empty, ΔWDR81-empty, and ΔWDR81-WDR81 cells were grown in 6-well plates (Greiner Bio-One). The cells were adsorbed with T3DCD or T1L at 5 PFUs/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium for 18 or 24 h at 37°C. The infected cells were lysed by two freeze-thaw cycles and the amount of infectious virus produced was measured using plaque assay.

Single-step VSV (GFP) and VSV-EBO GP (GFP) growth assay

NT, ΔCTSL, and ΔWDR81 cells were grown in 6-well plates (Greiner Bio-One). The cells were adsorbed with VSV (GFP) or VSV-EBO GP (GFP) at 5 PFUs/cell for 1 h at room temperature. After 1 h, the cells were washed three times with PBS and incubated in growth medium for 10 h (VSV [GFP]) or 18 h (VSV-EBO GP [GFP]) at 37°C. Cell media containing VSV (GFP) or VSV-EBO GP (GFP) were collected, and the virus titer was determined by plaque assay.

Conjugation of Alexa Fluor 488 to purified reovirus

Purified reovirus was labeled using the Alexa Fluor 488 Protein Labeling Kit (Invitrogen). Briefly, T3DCD virions (9×1013 particles/ml) were diluted into fresh 50 mM sodium bicarbonate (pH 8.5) and incubated in one vial of AF488 carboxylic acid, tetrafluorophenyl ester for 90 min at room temperature in the dark. After 90 min, the reaction was quenched by the addition of virus storage buffer (10 mM Tris-HCl, pH 7.4, 15 mM MgCl2, and 150 mM NaCl), and the labeled virions were layered onto 1.2- to 1.4-g/cm3 CsCl step gradients. The gradients were then centrifuged at 187,000×g for 4 h at 4°C. Bands corresponding to purified and labeled virions (~1.36 g/cm3) [33] were isolated and dialyzed into virus storage buffer (10 mM Tris-HCl, pH 7.4, 15 mM MgCl2, and 150 mM NaCl). Following dialysis, the particle concentration was determined by measuring the optical density of the purified virion stocks at 260 nm (OD260; 1 unit at OD260 = 2.1×1012 particles/ml) [33]. The purification of labeled virions was confirmed by SDS-PAGE and scanning for AF488 fluorescence using a ChemiDoc MP Imaging System (Bio-Rad).

Assessment of reovirus localization within an infected cell

NT, ΔCTSL, and ΔWDR81 cells were grown on a four chambered polystyrene vessel tissue culture treated glass slide (Corning). The cells were adsorbed with T3DCD (AF488) at 10,000 particles/cell for 1 h at 4°C. After 1 h, the chilled cells were washed three times with PBS and incubated in growth medium for 2 h at 37°C. The infected monolayers were then fixed with 200 μl of 3.7% formaldehyde for 10 min at room temperature and washed three times with PBS. When indicated, the fixed cells were stained with 200 μl of an anti-EEA1 (Cell Signaling), anti-Rab7 (Cell Signaling), or anti-LAMP1 (Abcam) primary antibody and with 200 μl of 1.0 μg/ml 4’,6-diamidino-2-phenylindole (DAPI; Invitrogen) diluted in PBS. The fixed and stained cells were washed with PBS and mounted using Aqua-Poly/Mount (Polysciences). Confocal images of infected cells were acquired using a Leica SP8 Scanning Confocal Microscope controlled by Leica-X software. The images were obtained using a X63 oil-immersion objective and White Light and 405 nm lasers and HyD detectors. Three-dimensional image stacks were acquired by recording sequential sections through the z-axis. All images were processed with ImageJ software (two-dimensional maximum intensity projections) [42]. Colocalization between AF488 and EEA1, Rab7, or LAMP1 was quantified using Just Another Colocalization Plugin (JACoP) [43].

Statistical analyses

Unless otherwise noted, the results from all experiments represent three or four biological replicates. Horizontal bars indicate the means. Error bars indicate the standard deviations. P values were calculated using one-way analysis of variance with Bonferroni Correction or Student’s t test (two-tailed, unequal variance assumed). For comparison of titers, two criteria were used to assign significance: P value of ≤ 0.05 and difference in titer of ≥ 1 log(PFU/ml) unit.

Results

CRISPR-Cas9 screen uncovers host factors that are required for reovirus infection

Toward the goal of identifying as yet unknown host factors that are required for reovirus infection of host cells, we undertook a genome-scale CRISPR-Cas9 positive selection screen in murine embryo fibroblasts (MEFs) derived from C57/BL6 mice. We selected MEFs for this screen because unlike transformed cells that are typically used to propagate and investigate reovirus infection, MEFs have a genomic makeup that resembles the normal diploid genome of the murine host. Additionally, multiple host factors that are important for reovirus infection and the host response have been identified or studied using MEFs [8,9,23,44,45]. To complete this screen, MEFs were transduced with lentiviruses derived from the Mouse CRISPR Knockout Pooled Library (GeCKO v2) in a one vector system, which encodes both Cas9 and a single-guide RNA (sgRNA). Transduced cells, which were selected with puromycin, were challenged with reovirus strain T3D-Cashdollar (T3DCD). T3DCD is significantly more cytotoxic than other laboratory isolates of T3D [29]. A small percentage of reovirus-resistant cells were obtained and subsequently expanded. The representation of sgRNAs in the transduced pool (prior to reovirus infection) and the reovirus-resistant pool (obtained following reovirus infection) was quantified by deep sequencing PCR products that were amplified from the genomic DNA (gDNA) (Fig 1A).

The GeCKO v2 library contains ~100,000 unique sgRNAs that target the mouse genome. Each gene is represented by 6 unique sgRNAs. The sequencing results were subjected to MAGeCK analysis, which ranks positively selected hits based on the number of sgRNAs enriched for each gene and the extent of enrichment of these sgRNAs following selection [37]. Using a false discovery rate (FDR) cut-off of ≤ 0.05, MAGeCK identified 7 significant hits (Fig 1B and 1C). These hits include SLC35A1 and CTSL, whose gene products are required for reovirus infection. SLC35A1 is necessary for the cell surface expression of sialic acid, which serves as a receptor for type 3 reovirus strains, such as T3D [46]. CTSL encodes the endosomal protease, cathepsin L, which is required for capsid disassembly, a necessary step in reovirus cell entry [23]. The five additional hits that were identified in our screen have not been directly tested through gene knockdown or knockout experiments to evaluate their function in reovirus infection. For our current study, we characterized the function of a poorly studied BEACH (beige and Chediak–Higashi)- and WD40 repeat-containing protein, WDR81. Interestingly, WDR81 interacts with WDR91 [27,28], which was also identified in our work (Fig 1B and 1C) and in another screen for proviral factors of reovirus infection [46].

To evaluate the function of WDR81 in reovirus infection, we used CRISPR-Cas9 editing to generate WDR81-deficient MEFs. Sequencing the gDNA of ΔWDR81 MEFs indicated that gene editing resulted in the introduction of a premature stop codon in the WDR81 open reading frame (Fig 1E). ΔCTSL MEFs, which were similarly generated by CRISPR-Cas9 editing, contained an in-frame deletion in the CTSL gene. ΔCTSL MEFs were used as a positive control cell line that is unable to support reovirus infection (Fig 1D). We first measured viability of control non-targeting (NT), ΔCTSL, and ΔWDR81 cells following infection with T3D. We found that the viability of NT cells decreased at 48 h post infection (hpi). In contrast, ΔCTSL, and ΔWDR81 remained resistant to reovirus-induced cell death (Fig 2A). These results validate our CRISPR-Cas9 screen. Further, our data suggest a previously unidentified role for WDR81 in impacting reovirus-induced cell death or a role for WDR81 in supporting events in reovirus infection, which ultimately affect reovirus-induced cell death.

Fig 2. Infection of WDR81-deficient cells by T3DCD.

Fig 2

(A) Induction of cell death. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD virions at 5 PFUs/cell. At 48 h post infection (hpi), the relative cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay. Horizontal bars indicate the means; ***, P ≤ 0.0005 (n = 4 biological replicates). (B) Schematic of the reovirus entry pathway. (C) Viral attachment. NT, ΔCTSL, and ΔWDR81 cells were adsorbed with T3DCD virions at 1.0×106 particles/cell, and the binding index was measured using indirect immunofluorescence. Horizontal bars indicate the means (n = 4 biological replicates). (D) Viral disassembly (virion-to-ISVP). NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD virions at 1.0×103 particles/cell. At the timepoints indicated in the figure, the levels of the reovirus μ1C and δ proteins and the PSTAIR epitope of the host protein Cdk1 were measured by Western blot. The migration of μ1C, δ, and PSTAIR are indicated on the left (n = 3 biological replicates; results from 1 representative experiment are shown). (E) Viral RNA transcription. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD virions at 5 PFUs/cell. At 6 and 18 hpi, the levels of the reovirus S1 gene transcript were measured using quantitative reverse transcription-PCR. Horizontal bars indicate the means; *, P ≤ 0.05, ***, P ≤ 0.0005 (n = 4 biological replicates). (F) Initiation of viral protein synthesis. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD virions at 5 PFUs/cell. At the timepoints indicated in the figure, the levels of the reovirus σNS protein and the PSTAIR epitope of the host protein Cdk1 were measured by Western blot. The migration of σNS and PSTAIR are indicated on the left (n = 3 biological replicates; results from 1 representative experiment are shown).

Reovirus fails to launch infection in the absence of WDR81

Reovirus initiates infection through the engagement of one or more cell surface receptors (Fig 2B). To determine whether the absence of WDR81 influences reovirus attachment, NT, ΔCTSL, and ΔWDR81 cells were adsorbed with reovirus, and the attached reovirus was quantified by indirect immunofluorescence. Our results demonstrate equivalent attachment of reovirus to each cell type (Fig 2C). These data indicate that ΔWDR81 does not influence reovirus attachment. Attached and internalized reovirus particles traffic through the endosomal-lysosomal system where they are acted on by luminal proteases, such as cathepsin L and B [23]. These proteases degrade the viral σ3 outer-capsid protein and cleave the μ1 protein to produce the particle-associated δ and ϕ fragments to form ISVPs (Fig 2B). As a marker for ISVP formation, we monitored the cleavage of μ1 into δ in NT, ΔCTSL, and ΔWDR81 cells. We found that δ was rapidly formed from μ1 in NT and ΔWDR81 cells (Fig 2D). In contrast, μ1 remained uncleaved in ΔCTSL cells due to the absence of functional cathepsin L. These data indicate that ΔWDR81 is not required for ISVP formation. Further, these results demonstrate that the absence of Cathepsin L and WDR81 renders cells resistant to reovirus-induced cell death via different mechanisms.

Successful disassembly of reovirus results in the delivery of the reovirus core particle to the host cytoplasm (Fig 2B) [6]. Cytoplasmically localized cores become transcriptionally active and synthesize viral mRNA using a viral RNA-dependent RNA polymerase, its cofactors, and capping machinery that are all contained within the core. The accumulation of viral S1 mRNA at 6 and 18 hpi was measured using RT-qPCR. We found that compared to NT cells, the levels of the S1 gene transcript in ΔCTSL and ΔWDR81 were substantially lower at each time point (Fig 2E). These data suggest that reovirus fails to efficiently launch infection in the absence of WDR81. Consistent with lower mRNA expression, we found that reovirus protein synthesis, as measured by the expression of the non-structural σNS protein, was not detected in ΔCTSL cells and is delayed in ΔWDR81 cells (Fig 2F). Reovirus infectivity was also measured by indirect immunofluorescence. Similar to the results shown above, reovirus infectivity was significantly lower in ΔCTSL and ΔWDR81 cells (Fig 3A). Importantly, the reductions in RNA synthesis and protein synthesis were sufficient to produce a diminishment in virus production (Fig 3B). In comparison to NT cells, virus production was strongly blocked in ΔCTSL cells. In contrast, an intermediate, but still significantly lower level of virus, was produced from ΔWDR81 cells. Since virus production from ΔWDR81 cells remained low over an extended time frame, these data suggest that infection is not simply slower in the absence of WDR81.

Fig 3. Infectivity of T3DCD and T1L virions in WDR81-deficient cells.

Fig 3

(A) Levels of infectivity. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD virions at 5 PFUs/cell. At 18 hpi, the infectivity index was measured using indirect immunofluorescence. Horizontal bars indicate the means; ***, P ≤ 0.0005 (n = 4 biological replicates). (B and C) Production of infectious virus. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD (B) or T1L (C) virions at 5 PFUs/cell. At 18 and 24 hpi, the amount of infectious virus produced was measured using plaque assay. Horizontal bars indicate the means; **, P ≤ 0.005, ***, P ≤ 0.0005 (n = 4 biological replicates).

The output of reovirus strain Type 1 Lang (T1L) was similarly reduced from ΔWDR81 cells (Fig 3C). Together, our data indicate that WDR81 is required for efficient reovirus replication. These results also suggest that a step after ISVP formation requires WDR81 (Fig 2D). Because viral RNA synthesis is the first step that is affected in the absence of WDR81, either RNA synthesis itself or events between ISVP formation and RNA synthesis, appear to require WDR81 (Fig 2E). Such steps could include ISVP-to-ISVP* conversion, pore formation, or core delivery into the host cytoplasm [47]. Because WDR81 directly affects the early events in infection, the increased survival of ΔWDR81 cells to reovirus infection is at least in part related to the inability of these cells to support reovirus infection. For the purpose of this study, we did not evaluate if the absence of WDR81 influences cell death independent of the capacity to allow reovirus infection.

Complementation of ΔWDR81 cells with human WDR81 restores sensitivity to reovirus infection

To ensure that the observed defect in reovirus infection was due to the genetic ablation of WDR81, we transduced ΔWDR81 cells with an empty lentivirus or a lentivirus that confers expression of 2xHA-tagged human WDR81 (hu-WDR81), which shares 88% homology with murine WDR81. Expression of hu-WDR81 in ΔWDR81-WDR81 cells, but not in ΔWDR81-empty cells, was confirmed by indirect immunofluorescence (Fig 4A). The complemented cells were challenged with reovirus to determine whether the expression of hu-WDR81 restores sensitivity to reovirus-induced cell death. As expected, NT-empty cells succumbed to infection in a time-dependent manner, whereas ΔWDR81-empty cells remained resistant. In contrast, ΔWDR81-WDR81 succumbed to reovirus infection, albeit to a slightly lower level than NT-empty cells (Fig 4B). We also measured reovirus infectivity in ΔWDR81-empty and ΔWDR81-WDR81 cells using indirect immunofluorescence. The infectivity of reovirus in ΔWDR81-empty cells was significantly lower than that of NT-empty cells. In contrast, the infectivity of reovirus was partially restored in ΔWDR81-WDR81 cells (Fig 4C). The incomplete complementation could be due to insufficient expression levels or because of less efficient interaction of hu-WDR81 with its murine partners. Nonetheless, whereas ΔWDR81-empty cells produced ~1.0 log10 fewer infectious particles than NT-empty cells, virus production from ΔWDR81-WDR81 cells was equivalent to NT-empty cells (Fig 4D). The phenotypic rescue of ΔWDR81 cells by the re-introduction of hu-WDR81 confirms a role for controlling an early event in reovirus replication.

Fig 4. Complementation of WDR81-deficient cells.

Fig 4

(A) WDR81 complementing cell lines. The levels of 2xHA-WDR81 in each cell line were determined by indirect immunofluorescence. The DRAQ5 (total cells) signal is false colored in red, and the IRDye 800CW (2xHA-WDR81) is false colored in green (n = 4 biological replicates; results for 1 representative experiment are shown). (B) Induction of cell death. NT-empty, ΔWDR81-empty, and ΔWDR81-WDR81 cells were infected with T3DCD virions at 5 PFUs/cell. At 24 and 48 h post infection (hpi), the relative cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay. Horizontal bars indicate the means; **, P ≤ 0.005, ***, P ≤ 0.0005 (n = 4 biological replicates). (C) Levels of infectivity. NT-empty, ΔWDR81-empty, and ΔWDR81-WDR81 cells were infected with T3DCD virions at 5 PFUs/cell. At 18 hpi, the infectivity index was measured using indirect immunofluorescence. Horizontal bars indicate the means; ***, P ≤ 0.0005 (n = 4 biological replicates). (D) Production of infectious virus. NT-empty, ΔWDR81-empty, and ΔWDR81-WDR81 cells were infected with T3DCD virions at 5 PFUs/cell. At 18 hpi, the amount of infectious virus produced was measured using plaque assay. Horizontal bars indicate the means; ***, P ≤ 0.0005 (n = 4 biological replicates).

WDR81 is dispensable for infection by reovirus ISVPs

In vitro treatment of virions with chymotrypsin results in the degradation of σ3 and the cleavage of μ1 to δ and ϕ to form ISVPs (Fig 5A and 5B) [34]. These particles remain intact and monodisperse in solution (Fig 5C). Moreover, in vitro generated ISVPs are indistinguishable from those that are formed within endosomes and, thus, are capable of launching infection [48]. Using a plate-based attachment assay, we found that ISVPs bind to the surface of NT, ΔCTSL, and ΔWDR81 cells with equivalent efficiency (Fig 5D). The S1 gene transcript accumulated to the same extent in NT, ΔCTSL, and ΔWDR81 cells (Fig 5E). Consistent with these results, the kinetics of σNS expression were similar between all cell types (Fig 5F). Compared to NT cells, the infectivity of ISVPs in ΔCTSL and in ΔWDR81 cells was only slightly lower (Fig 5G). Critically, each of the three cell types supported the production of reovirus progeny to an equivalent extent (Fig 5H). We observed comparable results when infection was initiated with ISVPs of strain T1L (Fig 5I). These data indicate that CTSL and WDR81 are dispensable for reovirus infection that is initiated by ISVPs. The mechanisms of reovirus RNA synthesis and protein synthesis are thought to be identical, regardless of whether the infection is initiated with virions or ISVPs. Thus, our data indicate that the steps following core delivery into the host cytoplasm (Fig 2B) are not dependent on the presence of WDR81.

Fig 5. Infection of WDR81-deficient cells by T3DCD or T1L ISVPs.

Fig 5

(A) Schematic of reovirus virions and ISVPs. (B) Protein compositions. T3DCD virions and ISVPs were analyzed by SDS-PAGE. The gel was Coomassie brilliant blue stained. The migration of capsid proteins is indicated on the left. μ1 resolves as μ1C, and μ1δ resolves as δ [74] (n = 4 biological replicates; results for 1 representative experiment are shown). (C) Size distribution profiles. T3DCD virions and ISVPs were analyzed by dynamic light scattering (n = 4 biological replicates; results from 1 representative experiment are shown). (D) Viral attachment. NT, ΔCTSL, and ΔWDR81 cells were adsorbed with T3DCD ISVPs at 1.0×106 particles/cell, and the binding index was measured using indirect immunofluorescence. Horizontal bars indicate the means (n = 4 biological replicates). (E) Viral RNA transcription. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD ISVPs at 5 PFUs/cell. At 6 h post infection (hpi), the levels of the reovirus S1 gene transcript were measured using quantitative reverse transcription-PCR. Horizontal bars indicate the means (n = 4 biological replicates). (F) Initiation of viral protein synthesis. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD ISVPs at 5 PFUs/cell. At the timepoints indicated in the figure, the levels of the reovirus σNS protein and the PSTAIR epitope of the host protein CDK1 were measured by Western blot. The migration of σNS and PSTAIR are indicated on the left (n = 3 biological replicates; results from 1 representative experiment are shown). (G) Levels of infectivity. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD ISVPs at 5 PFUs/cell. At 18 hpi, the infectivity index was measured using indirect immunofluorescence. Horizontal bars indicate the means; *, P ≤ 0.05 (n = 4 biological replicates). (H and I) Production of infectious virus. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD or T1L ISVPs at 5 PFUs/cell. At 18 hpi, the amount of infectious virus produced was measured using plaque assay. Horizontal bars indicate the means (n = 4 biological replicates).

Virions, but not ISVPs, accumulate in a dead-end compartment in the absence of WDR81

Because of the difference in the outcome of infection by virions and ISVPs (Figs 2 and 5), we sought to follow the fate of reovirus particles early in infection in NT, ΔCTSL, and ΔWDR81 cells. For this purpose, virions were chemically conjugated to Alexa Fluor 488 (AF488) and repurified. This labeling was most prominent on the σ3 and μ1 proteins (Fig 6A). The reovirus λ proteins were also labeled. The labeling does not affect the dispersion in solution as labeled and unlabeled particles showed an expected hydrodynamic diameter of ~100 nm (Fig 6B). Moreover, AF488-labeled particles produce plaques with the same specific infectivity as the unlabeled particles (Fig 6C). Upon infection of NT cells, AF488-labeled particles were found in cytoplasmic puncta, likely resembling endosomes. In ΔCTSL cells, even though the particles are unable to exit the endosome, the distribution of particles was similar to that observed in NT cells. In contrast, infection of ΔWDR81 cells produced puncta that appeared substantially larger and brighter, suggesting the presence of multiple particles at those sites (Fig 6D).

Fig 6. Infection of WDR81-deficient cells by T3DCD (AF488) virions.

Fig 6

(A) Protein compositions. Unlabeled and AF488-labeled T3DCD virions were analyzed by SDS-PAGE. The gel was Coomassie brilliant blue stained (left side panel) and scanned for AF488 fluorescence (right side panel). The migration of capsid proteins is indicated on the left. μ1 resolves as μ1C [74] (n = 4 biological replicates; results for 1 representative experiment are shown). (B) Size distribution profiles. Unlabeled and AF488-labeled T3DCD virions were analyzed by dynamic light scattering (n = 4 biological replicates; results from 1 representative experiment are shown). (C) Specific infectivity. The titers of unlabeled and AF488-labeled T3DCD virions (2×1012 particles/ml) were determined by plaque assay. Horizontal bars indicate the means (n = 4 biological replicates). (D) Localization within an infected cell. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD (AF488) at 10,000 virions/cell. At 2 h post infection (hpi), the infected monolayers were fixed, stained with DAPI, mounted, and imaged by confocal microscopy. The images were obtained using a X63 oil-immersion objective and processed using ImageJ software [42]. The DAPI signal is false colored in blue, and the AF488 signal is false colored in green. The inset boxes in the ‘Merge’ column are expanded in the ‘Merge (zoom)’ column. The scale bars represent 20 μm (n = 3 biological replicates; results from 1 representative experiment are shown).

Similar experiments were completed with AF488-labeled ISVPs that were generated using chymotrypsin. The δ fragment of ISVP-associated μ1 retained fluorescence signal along with the λ proteins (S1A Fig). Labeled ISVPs also remained monodisperse and infectious (S1B and S1C Fig). The distribution of ISVPs within infected NT and ΔCTSL cells was similar to that observed for virions in the same cell type (Figs 6D and S1D). Interestingly, the large puncta that were observed following infection of ΔWDR81 cells with virions were no longer present (Figs 6D and S1D). The distribution of ISVPs in ΔWDR81 cells was similar to the distribution in NT and ΔCTSL cells. Together, our data support the idea that the reduced capacity of virions to launch infection is related to their accumulation in a non-productive compartment due to the absence of WDR81. Because virion-to-ISVP conversion occurs normally in WDR81-deficient cells (Fig 2D), we think that ISVPs accumulate in this dead-end compartment.

During entry, reovirus is found in early, late, and recycling endosomes [22]. Preventing particle transit through EEA1-positive early endosomes and Rab7-positive late endosomes prevents a productive infection [22]. Further, transport of reovirus to LAMP1-positive compartments prevents efficient infection [24]. To define the subcellular location where reovirus particles were trapped in the absence of WDR81, we infected NT, ΔCTSL, and ΔWDR81 cells with AF488-labeled T3DCD virions and determined their localization with respect to EEA1-, Rab7- and LAMP1-positive compartments. In all three cell types, we observed an equivalent proportion of incoming virions that were localized with or near EEA1 (Figs 7 and S2A). In ΔWDR81 cells, EEA1 staining also showed enlarged donut-shaped structures, which are similar to those previously observed in the absence of this protein [27]. Some proportion of virions, especially the fraction that forms large puncta, was found enclosed within this compartment. In NT and ΔCTSL cells, virions were also associated with Rab7-positive structures, which is consistent with the known transit of reovirus to late endosomes [22] (Fig 8A). Remarkably, Rab7 staining was mostly absent in ΔWDR81 cells, and therefore, few reovirus particles were found associated with Rab7 structures (Figs 8A and S2B). Reovirus particles also colocalized with LAMP1 in all cell types (Figs 8B and S2C). Similar to the EEA1 results, LAMP1-positive donut-shaped compartments were observed in ΔWDR81 cells, which also harbored virus puncta. Based on previous findings that reovirus must reach late endosomes to launch infection [22], our data suggest that the absence of a Rab7-positive compartment in ΔWDR81 cells may account for the lack of infection. It is also possible that infection is blocked in ΔWDR81 cells because the particles are trapped in aberrant, donut like endolysosomal compartments.

Fig 7. Colocalization of T3DCD (AF488) virions with EEA1 in WDR81-deficient cells.

Fig 7

NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD (AF488) at 10,000 virions/cell. At 2 h post infection (hpi), the infected monolayers were fixed, stained with an anti-EEA1 primary antibody and with DAPI, mounted, and imaged by confocal microscopy. The images were obtained using a X63 oil-immersion objective and processed using ImageJ software [42]. The DAPI signal is false colored in blue, the AF488 signal is false colored in green, and the EEA1 signal is false colored in red. The white boxes highlight large virus puncta and/or EEA1 donut-shaped structures. The scale bars represent 10 μm (n = 3 biological replicates; results from 1 representative experiment are shown).

Fig 8. Colocalization of T3DCD (AF488) virions with Rab7 and LAMP1 in WDR81-deficient cells.

Fig 8

(A and B) NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD (AF488) at 10,000 virions/cell. At 2 h post infection (hpi), the infected monolayers were fixed, stained with an anti-Rab7 (A) or anti-LAMP1 (B) primary antibody and with DAPI, mounted, and imaged by confocal microscopy. The images were obtained using a X63 oil-immersion objective and processed using ImageJ software [42]. The DAPI signal is false colored in blue, the AF488 signal is false colored in green, and the Rab7 (A) or LAMP1 (B) signal is false colored in red. The white boxes highlight large virus puncta and/or LAMP1 donut-shaped structures. The scale bars represent 10 μm (n = 3 biological replicates; results from 1 representative experiment are shown).

WDR81 is required for infection by late penetrating viruses

Whereas reovirus virions must travel to late endosomes to launch infection, ISVPs can initiate infection either at the plasma membrane or from within early stages of the endocytic uptake pathway [18,49]. Based on our observation that infection by virions is blocked by the absence of WDR81 and infection by ISVPs is not, we hypothesized that WDR81 is required for the entry of other viruses that must transit through the late endosome to initiate infection. To test this idea, we used vesicular stomatitis virus (VSV), an early penetrating virus, and VSV that expresses the glycoprotein of Ebolavirus, a late penetrating virus, in place of the VSV G protein (VSV-EBO GP). Each of these viruses were engineered to express green fluorescent protein (GFP) in infected cells. Replacement of VSV G with EBOV GP switches the entry requirements of VSV to those needed for bona fide Ebolavirus infection [50,51].

We first tested the capacity of VSV (GFP) to compromise the viability of NT, ΔCTSL, and ΔWDR81 cells. Infection of NT cells with VSV (GFP) resulted in increasing cell death from 18 to 26 hpi (Fig 9A). Whereas cell death was delayed in VSV (GFP) infected ΔCTSL and ΔWDR81 cells, the differences between NT and either CTSL- or WDR81-deficient cells were modest by 26 h. The basis for these differences in cell death kinetics was not investigated further in this study. The capacity of VSV (GFP) to establish infection in these cell types was also tested by quantifying the fraction of GFP expressing cells over time using an Incucyte S3 Live Cell Imager. Starting from equally confluent monolayers (Fig 9C), we found that VSV (GFP) established infection with indistinguishable kinetics in all cell types (Fig 9D). Correspondingly, NT, ΔCTSL, and ΔWDR81 cells produced infectious progeny at similar levels (Fig 9E). Thus, WDR81 is dispensable for the replication of VSV (GFP) in MEFs.

Fig 9. Infection of WDR81-deficient cells by VSV (GFP) or VSV-EBO GP (GFP).

Fig 9

(A and B) Induction of cell death. NT, ΔCTSL, and ΔWDR81 cells were infected with VSV (GFP) (A) or VSV-EBO GP (GFP) (B) at 5 PFUs/cell. At 18 and 26 h post infection (hpi), the relative cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay. Horizontal bars indicate the means; *, P ≤ 0.05, **, P ≤ 0.005, ***, P ≤ 0.0005 (n = 4 biological replicates). (C, D, F, and G) Initiation of protein synthesis. NT, ΔCTSL, and ΔWDR81 cells were infected with VSV (GFP) (D) or VSV-EBO GP (GFP) (G) at 5 PFUs/cell. At the timepoints indicated in the figure, the number of total cells per image and the number of GFP positive cells per image were measured using the IncuCyte S3 Live-Cell Analysis System. The ‘Percent cell confluency’ at the 1 h timepoints is shown in panels C and F. Horizontal bars indicate the means (C and F); error bars indicate the standard deviations (D and G); *, P ≤ 0.05, ***, P ≤ 0.0005 (n = 4 biological replicates). (E and H) Production of infectious virus. NT, ΔCTSL, and ΔWDR81 cells were infected with VSV (GFP) (E) or VSV-EBO GP (GFP) (H) at 5 PFUs/cell. At 10 (E) or 18 (H) hpi, the amount of infectious virus produced was measured using plaque assay. Horizontal bars indicate the means; ***, P ≤ 0.0005 (n = 4 biological replicates).

We next tested the capacity of VSV-EBO GP (GFP) to affect the viability of NT, ΔCTSL, and ΔWDR81 cells. Whereas NT cells succumbed to VSV-EBO GP (GFP) infection within 26 h, the viability of CTSL- and WDR81-deficient cells was unaffected (Fig 9B). Cathepsin L activity is required for infection by Ebolavirus and VSV-EBO GP (GFP) [51]. Thus, the resistant phenotype of ΔCTSL cells was expected. To determine whether WDR81 is also required for infection by VSV-EBO GP (GFP), we quantified the appearance of GFP-positive cells over time. Starting from equally confluent monolayers (Fig 9F), we observed that NT cells were efficiently infected by VSV-EBO GP (GFP). In contrast, minimal GFP-positive cells were observed in ΔCTSL cells, whereas the infectivity of VSV-EBO GP (GFP) in ΔWDR81 cells was intermediate between NT and ΔCTSL cells (Fig 9G). Consistent with this, infectious progeny production by VSV-EBO GP (GFP) was reduced in absence of either cathepsin L or WDR81 (Fig 9H). Collectively, our results suggest that viruses that travel through the late endosome share a dependence on WDR81.

Discussion

In this manuscript, we present the results of a CRISPR-Cas9 knockout screen to identify host factors that are important for reovirus infection. We characterize the role of the endosomal protein WDR81. We find that in the absence of WDR81, reovirus particles are unable to launch viral gene expression and the viral replication program. The requirement for WDR81 is not unique to reovirus. We find that infection with VSV-EBO GP (GFP), which mimics the cell entry pathway of native Ebolavirus, is diminished by the absence of WDR81. Together, our work identifies a new host factor that is important for the entry of multiple viruses that traffic through late endosomes.

We show that infection by reovirus is dependent upon WDR81; in its absence, ISVPs are generated but do not continue the infectious cycle. These data suggest that ISVP-to-ISVP* conversion, pore formation, and/or core delivery require functional WDR81. Remarkably, these steps only require WDR81 when infection is initiated by virions. In vitro generated ISVPs remain capable of successfully completing virus replication [34]. Our data indicate that the requirements for the entry of in vitro generated ISVPs may be different. This idea is supported by another study demonstrating that endosomal cholesterol levels impact infection initiated by virions but not infection initiated by ISVPs [52]. These results counter the generally accepted assumption that once disassembled particles encounter a membrane, the remainder of the entry process (i.e., ISVP-to-ISVP* conversion, pore formation, and core delivery) is similar regardless of whether the infection was initiated by virions or ISVPs [5356]. One possible reason for this difference may be related to the site of membrane penetration. Extracellularly produced ISVPs are no longer dependent upon disassembly by endosomal proteases and, thus, can cross the plasma membrane or the membrane of an early-stage endocytic uptake vesicle [18,49]. In contrast, virions must transit through early endosomes and reach late endosomes to successfully launch infection [22]. Because WDR81 is localized to endosomal membranes, it is possible that it directly or indirectly influences the late stages of disassembly.

Early and late endosomes are marked by their respective resident Rab GTPases. During maturation, Rab5 in early endosomes is replaced by Rab7 in late endosomes [57]. This Rab switch is accompanied by a change in the type or content of phosphoinositide species [57]. Early endosomes predominantly contain phosphatidylinositol 3-phosphate (PtdIns3P). In contrast, late endosomes contain phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). Each Rab GTPase, along with the phosphatidylinositol type, recruits effector proteins and, therefore, influences the timely biogenesis and function of endosomes [57]. In WDR81- or WDR91-deficient cells, the levels of PtdIns3P increase because the activity of phosphatidylinositol 3-kinase (PI3K) is no longer repressed [28]. This results in the enlargement of the early endosomal compartment. In our own experiments, we observed such large donut-shaped structures in ΔWDR81 cells that stained with EEA1 and/or LAMP1. These structures may resemble improperly generated endolysosomal compartments. Our data also suggest that in cells lacking WDR81, Rab7 containing compartments are not formed. These data agree with previous evidence suggesting that WDR81 and WDR91 are required for maturation of endosomes [28]. In addition to WDR81 and WDR91, our screen uncovered two other proteins, Rab7 and CCZ1, that are required for endosomal maturation and reovirus infection. It is expected that the absence of Rab7, CCZ1, and WDR81 would produce similar phenotypes. As described above, the Rab5-to-Rab7 switch is a hallmark of endosome maturation. This step is stalled in the absence of Rab7 [5860]. CCZ1 serves as a guanine exchange factor for Rab7 [61,62]. In the absence of CCZ1, Rab7 remains inactive, leading to the blockade of endosome maturation. Considering the evidence that reovirus virions must reach the late endosome for a productive infection [22], our findings suggest that perturbations prevent the formation of functional late endosomes. Based on the observation that cathepsin mediated disassembly occurs normally in ΔWDR81 cells, our data suggest that some other aspect of the late endosomal environment, such as the presence of a specific protein, a characteristic lipid environment, or a precise pH, is important for infection. Indeed, membrane lipids and pH influence ISVP-to-ISVP* conversion in vitro [55,56,63]. Though the role of lipid composition in ISVP* formation during infection is unexplored, when reovirus ISVPs reach an over-acidified compartment, they fail to launch infection, likely due to failure to form ISVP*s [24,63].

Our work is congruent with a parallel study, which used CRISPR-Cas9 and RNA interference screens to identify Niemann-Pick C1 (NPC1) as a putative host factor for reovirus entry [52]. NPC1 mediates the transport of cholesterol from late endosomes and lysosomes to the endoplasmic reticulum [64]. NPC1-deficient cells are unable to support the delivery of transcriptionally active reovirus core particles to the host cytoplasm, whereas treatment with hydroxypropyl-β-cyclodextrin, which binds and solubilizes cholesterol, restores infection [52]. Thus, reovirus cannot launch infection from endocytic vesicles that are disrupted by the loss of WDR81 or NPC1. Whether the phenotypes produced from each of these deficiencies are related remains to be determined.

Similar to reovirus, Ebolavirus must transit through the late endosome to initiate infection [65,66]. Following attachment to cell surface receptors, Ebolavirus traffics to the endolysosomal compartment. Within endosomes, Ebolavirus GP is cleaved by cathepsin B and L to expose the intracellular receptor binding region [51]. Cleaved GP then interacts with NPC1 within late endosomes [31,50]. This interaction is necessary for eventual fusion of the viral and host membranes. Our results indicate that VSV-EBO GP (GFP), which follows the entry pathway of native Ebolavirus [51,67], fails to efficiently initiate infection in the absence of WDR81. Because cathepsin activity in ΔWDR81 cells is sufficient to disassemble reovirus, we expect that Ebolavirus GP cleavage also occurs in these cells. As such, our hypothesis is that VSV-EBO GP (GFP) cannot launch infection because particles containing cleaved GP do not reach NPC1 positive compartments. Alternatively, infection by VSV-EBO GP (GFP) is blocked at a step following NPC1 interaction [66]. Recent CRISPR-Cas9 screens to identify host factors that are required for coronavirus infection also identified WDR81 and/or WDR91 [6872]. The coronavirus spike protein is cleaved to become fusion competent [73]. This cleavage can occur at the plasma membrane (by the action of TMPRSS2) or within endosomes (by the action of cathepsin proteases). Work using spike mutants, which can only enter by one of these routes, suggests that WDR81-WDR91 are dispensable for plasma membrane entry but are required for endosomal entry [70]. The precise step in the coronavirus entry pathway that is dependent on WDR81-WDR91 is undefined. Nonetheless, our work demonstrates that aberrant trafficking in the absence of WDR81 is the basis for reduced infectivity for multiple late penetrating viruses.

Supporting information

S1 Fig. Infection of WDR81-deficient cells by T3DCD (AF488) ISVPs.

(A) Protein compositions. Unlabeled and AF488-labeled T3DCD ISVPs were analyzed by SDS-PAGE. The gel was Coomassie brilliant blue stained (left side panel) and scanned for AF488 fluorescence (right side panel). The migration of capsid proteins is indicated on the left. μ1δ resolves as δ [74] (n = 4 biological replicates; results for 1 representative experiment are shown). (B) Size distribution profiles. Unlabeled and AF488-labeled T3DCD ISVPs were analyzed by dynamic light scattering (n = 4 biological replicates; results from 1 representative experiment are shown). (C) Specific infectivity. The titers of unlabeled and AF488-labeled T3DCD ISVPs (2×1012 particles/ml) were determined by plaque assay. Horizontal bars indicate the means (n = 4 biological replicates). (D) Localization within an infected cell. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD (AF488) at 10,000 ISVPs/cell. At 2 h post infection (hpi), the infected monolayers were fixed, stained with DAPI, mounted, and imaged by confocal microscopy. The images were obtained using a X63 oil-immersion objective and processed using ImageJ software [42]. The DAPI signal is false colored in blue, and the AF488 signal is false colored in green. The inset boxes in the ‘Merge’ column are expanded in the ‘Merge (zoom)’ column. The scale bars represent 20 μm (n = 3 biological replicates; results from 1 representative experiment are shown).

(TIF)

S2 Fig. Quantification of colocalization between T3DCD (AF488) virions and EEA1, Rab7, or LAMP1 in WDR81-deficient cells.

(A-C) NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD (AF488) at 10,000 virions/cell. At 2 h post infection (hpi), the infected monolayers were fixed, stained with an anti-EEA1, anti-Rab7, or anti-LAMP1 primary antibody and with DAPI, mounted, and imaged by confocal microscopy. The images were obtained using a X63 oil-immersion objective and processed using ImageJ software [42]. Pearson’s correlation coefficient between AF488 and EEA1 (A), Rab7 (B), or LAMP1 (C) was calculated using Just Another Colocalization Plugin (JACoP) [43]. Horizontal bars indicate the means; **, P ≤ 0.005 (n = 3 biological replicates).

(TIF)

S1 Data. Numerical values that were used to generate Tables and Figures in the manuscript are included. Each tab represents data for a different figure.

(XLSX)

Acknowledgments

We thank members of our laboratory and the Indiana University virology community for helpful suggestions. We are also grateful to Dr. Terry Dermody (University of Pittsburgh) for review of our manuscript and for sharing their unpublished results. Next generation sequencing was performed in the Indiana University Center for Genomics and Bioinformatics. Dynamic light scattering was performed in the Indiana University Physical Biochemistry Instrumentation Facility. Confocal microscopy was performed in the Indiana University Light Microscopy Imaging Center.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award numbers R01AI110637 and R03AI142013 (PD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Hirsch AJ. The use of RNAi-based screens to identify host proteins involved in viral replication. Future Microbiol. 2010;5(2):303–11. Epub 2010/02/11. doi: 10.2217/fmb.09.121 ; PubMed Central PMCID: PMC2864646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Puschnik AS, Majzoub K, Ooi YS, Carette JE. A CRISPR toolbox to study virus-host interactions. Nat Rev Microbiol. 2017;15(6):351–64. Epub 2017/04/20. doi: 10.1038/nrmicro.2017.29 ; PubMed Central PMCID: PMC5800792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Carette JE, Guimaraes CP, Wuethrich I, Blomen VA, Varadarajan M, Sun C, et al. Global gene disruption in human cells to assign genes to phenotypes by deep sequencing. Nat Biotechnol. 2011;29(6):542–6. doi: 10.1038/nbt.1857 ; PubMed Central PMCID: PMC3111863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bailey AL, Diamond MS. A Crisp(r) New Perspective on SARS-CoV-2 Biology. Cell. 2021;184(1):15–7. Epub 2020/12/19. doi: 10.1016/j.cell.2020.12.003 ; PubMed Central PMCID: PMC7746090 NGM Biopharmaceuticals, and the Carnival Corporation and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has received unrelated funding support from Moderna, Vir Biotechnology, and Emergent BioSolutions. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Flint M, Chatterjee P, Lin DL, McMullan LK, Shrivastava-Ranjan P, Bergeron E, et al. A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus. Nat Commun. 2019;10(1):285. Epub 2019/01/19. doi: 10.1038/s41467-018-08135-4 ; PubMed Central PMCID: PMC6336797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dermody TS, Parker JC, Sherry B. Orthoreoviruses. In: Knipe DM, Howley PM, editors. Fields Virology. 2. Sixth ed. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1304–46. [Google Scholar]
  • 7.Holm GH, Pruijssers AJ, Li L, Danthi P, Sherry B, Dermody TS. Interferon regulatory factor 3 attenuates reovirus myocarditis and contributes to viral clearance. J Virol. 2010;84(14):6900–8. Epub 2010/05/14. doi: 10.1128/JVI.01742-09 ; PubMed Central PMCID: PMC2898218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Holm GH, Zurney J, Tumilasci V, Leveille S, Danthi P, Hiscott J, et al. Retinoic acid-inducible gene-I and interferon-beta promoter stimulator-1 augment proapoptotic responses following mammalian reovirus infection via interferon regulatory factor-3. J Biol Chem. 2007;282(30):21953–61. doi: 10.1074/jbc.M702112200 . [DOI] [PubMed] [Google Scholar]
  • 9.Danthi P, Pruijssers AJ, Berger AK, Holm GH, Zinkel SS, Dermody TS. Bid regulates the pathogenesis of neurotropic reovirus. PLoS Pathog. 2010;6:e1000980. Epub 2010/07/10. doi: 10.1371/journal.ppat.1000980 ; PubMed Central PMCID: PMC2895667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Danthi P, Coffey CM, Parker JS, Abel TW, Dermody TS. Independent regulation of reovirus membrane penetration and apoptosis by the mu1 phi domain. PLoS Pathog. 2008;4(12):e1000248. Epub 2008/12/30. doi: 10.1371/journal.ppat.1000248 ; PubMed Central PMCID: PMC2600812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Stencel-Baerenwald J, Reiss K, Blaum BS, Colvin D, Li XN, Abel T, et al. Glycan engagement dictates hydrocephalus induction by serotype 1 reovirus. MBio. 2015;6(2):e02356. doi: 10.1128/mBio.02356-14 ; PubMed Central PMCID: PMC4358001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Reiss K, Stencel JE, Liu Y, Blaum BS, Reiter DM, Feizi T, et al. The GM2 glycan serves as a functional coreceptor for serotype 1 reovirus. PLoS Pathog. 2012;8(12):e1003078. Epub 2012/12/14. doi: 10.1371/journal.ppat.1003078 ; PubMed Central PMCID: PMC3516570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Reiter DM, Frierson JM, Halvorson EE, Kobayashi T, Dermody TS, Stehle T. Crystal structure of reovirus attachment protein sigma1 in complex with sialylated oligosaccharides. PLoS Pathog. 2011;7(8):e1002166. Epub 2011/08/11. doi: 10.1371/journal.ppat.1002166 ; PubMed Central PMCID: PMC3150272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, Schnell FJ, et al. Junction adhesion molecule is a receptor for reovirus. Cell. 2001;104(3):441–51. Epub 2001/03/10. doi: 10.1016/s0092-8674(01)00231-8 . [DOI] [PubMed] [Google Scholar]
  • 15.Konopka-Anstadt JL, Mainou BA, Sutherland DM, Sekine Y, Strittmatter SM, Dermody TS. The Nogo receptor NgR1 mediates infection by mammalian reovirus. Cell Host Microbe. 2014;15(6):681–91. doi: 10.1016/j.chom.2014.05.010 ; PubMed Central PMCID: PMC4100558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Maginnis MS, Forrest JC, Kopecky-Bromberg SA, Dickeson SK, Santoro SA, Zutter MM, et al. Beta1 integrin mediates internalization of mammalian reovirus. J Virol. 2006;80(6):2760–70. Epub 2006/02/28. 80/6/2760 [pii] doi: 10.1128/JVI.80.6.2760-2770.2006 ; PubMed Central PMCID: PMC1395463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Koehler M, Petitjean SJL, Yang J, Aravamudhan P, Somoulay X, Lo Giudice C, et al. Reovirus directly engages integrin to recruit clathrin for entry into host cells. Nat Commun. 2021;12(1):2149. Epub 2021/04/14. doi: 10.1038/s41467-021-22380-0 ; PubMed Central PMCID: PMC8041799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Boulant S, Stanifer M, Kural C, Cureton DK, Massol R, Nibert ML, et al. Similar uptake but different trafficking and escape routes of reovirus virions and infectious subvirion particles imaged in polarized Madin-Darby canine kidney cells. Mol Biol Cell. 2013;24(8):1196–207. Epub 2013/02/22. doi: 10.1091/mbc.E12-12-0852 ; PubMed Central PMCID: PMC3623640. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Schulz WL, Haj AK, Schiff LA. Reovirus uses multiple endocytic pathways for cell entry. J Virol. 2012;86(23):12665–75. Epub 2012/09/14. doi: 10.1128/JVI.01861-12 ; PubMed Central PMCID: PMC3497677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Maginnis MS, Mainou BA, Derdowski A, Johnson EM, Zent R, Dermody TS. NPXY motifs in the beta1 integrin cytoplasmic tail are required for functional reovirus entry. J Virol. 2008;82(7):3181–91. Epub 2008/01/25. JVI.01612-07 [pii] doi: 10.1128/JVI.01612-07 ; PubMed Central PMCID: PMC2268482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mainou BA, Dermody TS. Src kinase mediates productive endocytic sorting of reovirus during cell entry. J Virol. 2011;85(7):3203–13. Epub 2011/01/21. doi: 10.1128/JVI.02056-10 ; PubMed Central PMCID: PMC3067878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Mainou BA, Dermody TS. Transport to late endosomes is required for efficient reovirus infection. J Virol. 2012;86(16):8346–58. Epub 2012/06/08. doi: 10.1128/JVI.00100-12 ; PubMed Central PMCID: PMC3421701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ebert DH, Deussing J, Peters C, Dermody TS. Cathepsin L and cathepsin B mediate reovirus disassembly in murine fibroblast cells. J Biol Chem. 2002;277(27):24609–17. Epub 2002/05/03. doi: 10.1074/jbc.M201107200 . [DOI] [PubMed] [Google Scholar]
  • 24.Chandran K, Parker JS, Ehrlich M, Kirchhausen T, Nibert ML. The delta region of outer-capsid protein m1 undergoes conformational change and release from reovirus particles during cell entry. Journal of Virology. 2003;77(24):13361–75. doi: 10.1128/jvi.77.24.13361-13375.2003 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Knowlton JJ, Fernandez de Castro I, Ashbrook AW, Gestaut DR, Zamora PF, Bauer JA, et al. The TRiC chaperonin controls reovirus replication through outer-capsid folding. Nat Microbiol. 2018;3(4):481–93. Epub 2018/03/14. doi: 10.1038/s41564-018-0122-x ; PubMed Central PMCID: PMC5874176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Knowlton JJ, Gestaut D, Ma B, Taylor G, Seven AB, Leitner A, et al. Structural and functional dissection of reovirus capsid folding and assembly by the prefoldin-TRiC/CCT chaperone network. Proc Natl Acad Sci U S A. 2021;118(11). Epub 2021/04/11. doi: 10.1073/pnas.2018127118 ; PubMed Central PMCID: PMC7980406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rapiteanu R, Davis LJ, Williamson JC, Timms RT, Paul Luzio J, Lehner PJ. A Genetic Screen Identifies a Critical Role for the WDR81-WDR91 Complex in the Trafficking and Degradation of Tetherin. Traffic. 2016;17(8):940–58. Epub 2016/04/30. doi: 10.1111/tra.12409 ; PubMed Central PMCID: PMC5025723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Liu K, Jian Y, Sun X, Yang C, Gao Z, Zhang Z, et al. Negative regulation of phosphatidylinositol 3-phosphate levels in early-to-late endosome conversion. J Cell Biol. 2016;212(2):181–98. Epub 2016/01/20. doi: 10.1083/jcb.201506081 ; PubMed Central PMCID: PMC4738380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Coffey CM, Sheh A, Kim IS, Chandran K, Nibert ML, Parker JS. Reovirus outer capsid protein m1 induces apoptosis and associates with lipid droplets, endoplasmic reticulum, and mitochondria. Journal of Virology. 2006;80(17):8422–38. doi: 10.1128/JVI.02601-05 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kobayashi T, Ooms LS, Ikizler M, Chappell JD, Dermody TS. An improved reverse genetics system for mammalian orthoreoviruses. Virology. 2010;398(2):194–200. Epub 2010/01/01. doi: 10.1016/j.virol.2009.11.037 ; PubMed Central PMCID: PMC2823833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. 2012;31(8):1947–60. Epub 2012/03/08. doi: 10.1038/emboj.2012.53 ; PubMed Central PMCID: PMC3343336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Berard A, Coombs KM. Mammalian reoviruses: propagation, quantification, and storage. Curr Protoc Microbiol. 2009;Chapter 15:Unit15C 1. Epub 2009/08/05. doi: 10.1002/9780471729259.mc15c01s14 . [DOI] [PubMed] [Google Scholar]
  • 33.Smith RE, Zweerink HJ, Joklik WK. Polypeptide components of virions, top component and cores of reovirus type 3. Virology. 1969;39(4):791–810. doi: 10.1016/0042-6822(69)90017-8 [DOI] [PubMed] [Google Scholar]
  • 34.Nibert ML, Chappell JD, Dermody TS. Infectious subvirion particles of reovirus type 3 Dearing exhibit a loss in infectivity and contain a cleaved s1 protein. Journal of Virology. 1995;69:5057–67. doi: 10.1128/JVI.69.8.5057-5067.1995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Middleton JK, Severson TF, Chandran K, Gillian AL, Yin J, Nibert ML. Thermostability of reovirus disassembly intermediates (ISVPs) correlates with genetic, biochemical, and thermodynamic properties of major surface protein mu1. J Virol. 2002;76(3):1051–61. Epub 2002/01/05. doi: 10.1128/jvi.76.3.1051-1061.2002 ; PubMed Central PMCID: PMC135780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11(8):783–4. Epub 2014/07/31. doi: 10.1038/nmeth.3047 ; PubMed Central PMCID: PMC4486245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol. 2014;15(12):554. doi: 10.1186/s13059-014-0554-4 ; PubMed Central PMCID: PMC4290824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Thete D, Snyder AJ, Mainou BA, Danthi P. Reovirus mu1 Protein Affects Infectivity by Altering Virus-Receptor Interactions. J Virol. 2016;90(23):10951–62. Epub 2016/09/30. doi: 10.1128/JVI.01843-16 ; PubMed Central PMCID: PMC5110151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Wetzel JD, Chappell JD, Fogo AB, Dermody TS. Efficiency of viral entry determines the capacity of murine erythroleukemia cells to support persistent infections by mammalian reoviruses. J Virol. 1997;71(1):299–306. Epub 1997/01/01. doi: 10.1128/JVI.71.1.299-306.1997 ; PubMed Central PMCID: PMC191051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8. doi: 10.1038/nprot.2008.73 . [DOI] [PubMed] [Google Scholar]
  • 41.Becker MM, Peters TR, Dermody TS. Reovirus sigma NS and mu NS proteins form cytoplasmic inclusion structures in the absence of viral infection. J Virol. 2003;77(10):5948–63. Epub 2003/04/30. doi: 10.1128/jvi.77.10.5948-5963.2003 ; PubMed Central PMCID: PMC154006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–5. Epub 2012/08/30. doi: 10.1038/nmeth.2089 ; PubMed Central PMCID: PMC5554542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Bolte S, Cordelieres FP. A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006;224(Pt 3):213–32. Epub 2007/01/11. doi: 10.1111/j.1365-2818.2006.01706.x . [DOI] [PubMed] [Google Scholar]
  • 44.Connolly JL, Rodgers SE, Clarke P, Ballard DW, Kerr LD, Tyler KL, et al. Reovirus-induced apoptosis requires activation of transcription factor NF-kappaB. J Virol. 2000;74(7):2981–9. Epub 2000/03/09. doi: 10.1128/jvi.74.7.2981-2989.2000 ; PubMed Central PMCID: PMC111796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Antar AA, Konopka JL, Campbell JA, Henry RA, Perdigoto AL, Carter BD, et al. Junctional adhesion molecule-A is required for hematogenous dissemination of reovirus. Cell Host Microbe. 2009;5(1):59–71. Epub 2009/01/22. S1931-3128(08)00398-3 [pii] doi: 10.1016/j.chom.2008.12.001 ; PubMed Central PMCID: PMC2642927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Urbanek K, Sutherland DM, Orchard RC, Wilen CB, Knowlton JJ, Aravamudhan P, et al. Cytidine Monophosphate N-Acetylneuraminic Acid Synthetase and Solute Carrier Family 35 Member A1 Are Required for Reovirus Binding and Infection. J Virol. 2020;95(2). Epub 2020/10/23. doi: 10.1128/JVI.01571-20 ; PubMed Central PMCID: PMC7944449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Gummersheimer SL, Snyder AJ, Danthi P. Control of Capsid Transformations during Reovirus Entry. Viruses. 2021;13(2). Epub 2021/01/27. doi: 10.3390/v13020153 ; PubMed Central PMCID: PMC7911961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Nibert ML, Chappell JD, Dermody TS. Infectious subvirion particles of reovirus type 3 Dearing exhibit a loss in infectivity and contain a cleaved sigma 1 protein. J Virol. 1995;69(8):5057–67. Epub 1995/08/01. doi: 10.1128/JVI.69.8.5057-5067.1995 ; PubMed Central PMCID: PMC189323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Borsa J, Morash BD, Sargent MD, Copps TP, Lievaart PA, Szekely JG. Two modes of entry of reovirus particles into L cells. Journal of General Virology. 1979;45:161–70. doi: 10.1099/0022-1317-45-1-161 [DOI] [PubMed] [Google Scholar]
  • 50.Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature. 2011;477(7364):340–3. Epub 2011/08/26. doi: 10.1038/nature10348 ; PubMed Central PMCID: PMC3175325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science. 2005;308(5728):1643–5. doi: 10.1126/science.1110656 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Ortega-Gonzalez P, Taylor G, Jangra RK, Tenorio R, de Castro IF, Mainou BA, et al. Reovirus infection is regulated by NPC1 and endosomal cholesterol homeostasis. bioRxiv. 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Agosto MA, Ivanovic T, Nibert ML. Mammalian reovirus, a nonfusogenic nonenveloped virus, forms size-selective pores in a model membrane. Proceedings of the National Academy of Sciences USA. 2006;103(44):16496–501. doi: 10.1073/pnas.0605835103 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Ivanovic T, Agosto MA, Zhang L, Chandran K, Harrison SC, Nibert ML. Peptides released from reovirus outer capsid form membrane pores that recruit virus particles. Embo J. 2008;27:1289–98. doi: 10.1038/emboj.2008.60 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Snyder AJ, Danthi P. Lipid Membranes Facilitate Conformational Changes Required for Reovirus Cell Entry. J Virol. 2015;90(5):2628–38. doi: 10.1128/JVI.02997-15 ; PubMed Central PMCID: PMC4810687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Snyder AJ, Danthi P. Lipids Cooperate with the Reovirus Membrane Penetration Peptide to Facilitate Particle Uncoating. J Biol Chem. 2016;291(52):26773–85. doi: 10.1074/jbc.M116.747477 ; PubMed Central PMCID: PMC5207185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Huotari J, Helenius A. Endosome maturation. EMBO J. 2011;30(17):3481–500. Epub 2011/09/01. doi: 10.1038/emboj.2011.286 ; PubMed Central PMCID: PMC3181477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Press B, Feng Y, Hoflack B, Wandinger-Ness A. Mutant Rab7 causes the accumulation of cathepsin D and cation-independent mannose 6-phosphate receptor in an early endocytic compartment. J Cell Biol. 1998;140(5):1075–89. Epub 1998/04/18. doi: 10.1083/jcb.140.5.1075 ; PubMed Central PMCID: PMC2132709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Vitelli R, Santillo M, Lattero D, Chiariello M, Bifulco M, Bruni CB, et al. Role of the small GTPase Rab7 in the late endocytic pathway. J Biol Chem. 1997;272(7):4391–7. Epub 1997/02/14. doi: 10.1074/jbc.272.7.4391 . [DOI] [PubMed] [Google Scholar]
  • 60.Feng Y, Press B, Wandinger-Ness A. Rab 7: an important regulator of late endocytic membrane traffic. J Cell Biol. 1995;131(6 Pt 1):1435–52. Epub 1995/12/01. doi: 10.1083/jcb.131.6.1435 PubMed Central PMCID: PMC2120682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Wang CW, Stromhaug PE, Shima J, Klionsky DJ. The Ccz1-Mon1 protein complex is required for the late step of multiple vacuole delivery pathways. J Biol Chem. 2002;277(49):47917–27. Epub 2002/10/05. doi: 10.1074/jbc.M208191200 ; PubMed Central PMCID: PMC2754690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Nordmann M, Cabrera M, Perz A, Brocker C, Ostrowicz C, Engelbrecht-Vandre S, et al. The Mon1-Ccz1 complex is the GEF of the late endosomal Rab7 homolog Ypt7. Curr Biol. 2010;20(18):1654–9. Epub 2010/08/28. doi: 10.1016/j.cub.2010.08.002 . [DOI] [PubMed] [Google Scholar]
  • 63.Thete D, Danthi P. Conformational changes required for reovirus cell entry are sensitive to pH. Virology. 2015;483:291–301. doi: 10.1016/j.virol.2015.04.025 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Watari H, Blanchette-Mackie EJ, Dwyer NK, Glick JM, Patel S, Neufeld EB, et al. Niemann-Pick C1 protein: obligatory roles for N-terminal domains and lysosomal targeting in cholesterol mobilization. Proc Natl Acad Sci U S A. 1999;96(3):805–10. Epub 1999/02/03. doi: 10.1073/pnas.96.3.805 ; PubMed Central PMCID: PMC15306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA. Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog. 2010;6(9):e1001110. Epub 2010/09/24. doi: 10.1371/journal.ppat.1001110 ; PubMed Central PMCID: PMC2940741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Spence JS, Krause TB, Mittler E, Jangra RK, Chandran K. Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway. mBio. 2016;7(1):e01857–15. Epub 2016/02/11. doi: 10.1128/mBio.01857-15 ; PubMed Central PMCID: PMC4752599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Chandran K, Farsetta DL, Nibert ML. Strategy for nonenveloped virus entry: a hydrophobic conformer of the reovirus membrane penetration protein m1 mediates membrane disruption. Journal of Virology. 2002;76(19):9920–33. doi: 10.1128/jvi.76.19.9920-9933.2002 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Wang R, Simoneau CR, Kulsuptrakul J, Bouhaddou M, Travisano K, Hayashi JM, et al. Functional genomic screens identify human host factors for SARS-CoV-2 and common cold coronaviruses. bioRxiv. 2020. Epub 2020/10/01. doi: 10.1101/2020.09.24.312298 ; PubMed Central PMCID: PMC7523113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Daniloski Z, Jordan TX, Wessels HH, Hoagland DA, Kasela S, Legut M, et al. Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. Cell. 2021;184(1):92–105 e16. Epub 2020/11/05. doi: 10.1016/j.cell.2020.10.030 ; PubMed Central PMCID: PMC7584921. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Zhu Y, Feng F, Hu G, Wang Y, Yu Y, Zhu Y, et al. A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. Nat Commun. 2021;12(1):961. Epub 2021/02/13. doi: 10.1038/s41467-021-21213-4 ; PubMed Central PMCID: PMC7878750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Grodzki M, Bluhm AP, Schäfer M, Tagmount A, Russo M, Sobh A, et al. Genome-scale CRISPR Screens Identify Host Factors that Promote Human Coronavirus Infection. bioRxiv. 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Poston D, Weisblum Y, Hobbs A, Bieniasz PD. VPS29 exerts opposing effects on endocytic viral entry. bioRxiv. 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Heald-Sargent T, Gallagher T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses. 2012;4(4):557–80. Epub 2012/05/17. doi: 10.3390/v4040557 ; PubMed Central PMCID: PMC3347323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Nibert ML, Odegard AL, Agosto MA, Chandran K, Schiff LA. Putative autocleavage of reovirus m1 protein in concert with outer-capsid disassembly and activation for membrane permeabilization. Journal of Molecular Biology. 2005;345(3):461–74. doi: 10.1016/j.jmb.2004.10.026 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Christopher F Basler, Christiane E Wobus

7 Nov 2021

Dear Dr. Danthi,

Thank you very much for submitting your manuscript "A CRISPR-Cas9 screen reveals a role for WD repeat-containing protein 81 (WDR81) in the entry of late penetrating viruses" for consideration at PLOS Pathogens. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

All reviewers appreciated the attention to an interesting topic in reovrus biology but some expressed the need for more mechanistic studies. Therefore, in your revision, please pay particular attention to those studies that speak to the mechanism of action of WDR81's inhibition of reovirus entry, its location, and the identification of the cellular compartment of where it acts.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Christiane E. Wobus

Associate Editor

PLOS Pathogens

Christopher Basler

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Reviewer's Responses to Questions

Part I - Summary

Please use this section to discuss strengths/weaknesses of study, novelty/significance, general execution and scholarship.

Reviewer #1: A CRISPR-Cas9 screen reveals a role for WD repeat-containing protein 81 (WDR81) in the entry of late penetrating viruses

By AJ Snyder et al (Corresponding author: P Danthi)

Submitted to PLoS Pathog (Editorial No. PPATHOGENS-D-21-01986)

General Comments

In the search for host factors affecting different steps of orthoreovirus (reovirus) replication, a CRISPR-Cas9 knockout (KO) screen was performed on fibroblasts derived from embryonic tissue of C57/BL6 mice. Seven cellular genes were identified (WDR81, WRD91, RAB7, CCZ1, CTSL, GNPTAB, and SLC35A1) which were required for the induction of cell death following reovirus infection. The work reported here concentrated on the WD repeat-containing protein 81 (WDR81) which is involved in the maturation of endosomes (to late endosomes) required for reovirus replication. KO of WDR81 rendered cells resistant to reovirus infection. Conversely, when delta-WDR81 cells were complemented by expression of WDR81 in trans (from a transduced vector), susceptibility to reovirus infection was restored. Detailed knowledge of the different steps of the reovirus replication cycle permitted authors to localize the step of reovirus replication affected by the WDR81 KO. Since Ebolavirus requires late endosomes for its replication as well, it could be shown that the replication of a vesicular stomatitis virus (VSV)-Ebolavirus glycoprotein (GP) recombinant (labelled with GFP) was also affected by WDR81 KO (whereas replication of VSV exiting the endosomes at an early stage was not).

The Introduction on a complex subject is succinct; it could be slightly shortened. The Methods used are meticulously described. The Results are clearly presented; some of the figures shown could be improved for transparency. The Discussion does justice to the data; it could also be slightly shortened. The differentiation of reovirus infection and replication should be clarified.

This reviewer has only relatively minor additional Specific Comments.

Reviewer #2: Snyder et al conducted a screen to identify cellular genes that are required for efficient reovirus infection, using a lentivirus-derived CRISPR library transduced into murine embryonic fibroblasts. They identified seven genes whose CRISPR-mediated genetic ablation resulted in resistance to reovirus-dependent cell killing. The identification of cathepsin L, which is known to be required for the reovirus entry pathway, as one of those seven validated the use of this screening technology to identify additional required genes. The authors focused on WDR81, a protein involved in endosome maturation, and confirm that cells deficient in WDR81 are resistant to infection. Using various biochemical and genetic techniques, they show that cells lacking WDR81 fail to support reovirus infection at a step following endosomal proteolysis of the outer capsid to generate infectious subviral particles (ISVPs) and prior to nascent viral RNA synthesis, resulting in a 1.5-log reduction in infectious virus particle production. This effect was reovirus strain-independent, as both the T3DCD and T1L strains were affected by the loss of WDR81. Importantly, complementation of the WDR81-deficient cells with a lentivirus expressing wild type WDR81 restored susceptibility to reovirus infection, suggesting that the effect was specific to the genetic ablation of WDR81. Interestingly, infection with exogenously produced ISVPs was not altered by the absence of WDR81, suggesting that WDR81 facilitates cytoplasmic entry of ISVPs generated in endosomal compartments, but not ISVPs mediating host cell entry through other pathways. Confocal microscopy demonstrated accumulation of fluorophore-tagged virions, but not fluorophore-tagged ISVPs, in a subcellular “dead end” compartment in the absence of WDR81, again suggesting a defect in the endosomal entry process. Finally, the authors demonstrate that WDR81 deficiency inhibits entry of VSV pseudotyped with the EBOV glycoprotein, which requires trafficking to late endosomes for cellular entry, but has no effect on native VSV, which does not. Together, these data suggest a role for WDR81 in facilitating entry of viruses that depend on the function of late endosomes to allow for cytoplasmic delivery of viral particles.

This manuscript represents a significant step forward in the identification of host cell machinery that facilitate reovirus entry following endocytic uptake. The data are presented effectively and include appropriate controls and statistical analysis. Weaknesses of the manuscript include the lack of data to 1) identify the nature of the “dead end” compartment to which reovirus particles traffic in the absence of WDR81; and 2) determine whether reovirus particles localize to WDR81-containing endosomes during the entry process, which might at least start to give some clues about a potential mechanism. Other experiments that attempt to elucidate a mechanism for WDR81 in the reovirus entry pathway would certainly enhance the significance of the work. One final major issue has to do with the time points examined in some of the experiments. Based on the data in Fig. 2F, WDR81-deficient cells exhibit only a two hour delay in the synthesis of σNS compared to wild type cells (a strong band appearing at 12 hpi rather than 10 hpi). This is hard to reconcile with the level of decrease in infectivity and infectious titer shown at 18 hpi (as well as the much lower levels of transcription observed at 6 hpi). If reovirus protein synthesis is merely delayed by 2 h (which the authors claim is “significantly delayed”), in a single cycle replication assay (which would presumably be close to the case at an MOI of 5 PFU/cell), would the levels of virus in WDR81-deficient cells ever “catch up” to levels in wild type cells, if measured at 24 or 36 hpi? If it does not, then perhaps there are additional roles for WDR81 in facilitating cell death in response to infection (which would be more in accordance with the longer term selection of cells resistant to reovirus-induced cell death that formed the basis for the CRISPR screen). A longer time course looking at RNA levels, as well as infectivity and viral titers, would help resolve these issues.

Reviewer #3: Snyder et al., performed CRISPR-Cas9 based genome-wide screening for finding host genes related to mammalian reovirus infection. In the initial screening, several candidate genes which promote virus infections were detected along with several genes that have been studied. Among those genes that have not been investigated, authors focused on the WD repeat-containing protein 81 (WDR81) which was related to the maturation of endosomes. By using assays to evaluate virus binding and penetration, the authors concluded that without WDR81, mammalian reovirus virion is stacked inside the endosome (authors called ‘in the dead-end compartment). Lastly, the authors found that the infectivity of vesicular stomatitis virus carrying ebolavirus glycoprotein (VSV-EBO GP) but not wild-type VSV were reduced in WDR81 knock-out cells and concluded that WDR81 is important for the penetration steps of late penetrating viruses which transit through the late endosome to initiate infection. Although the manuscript is very well written and opens a new paradigm about reovirus endocytosis that remains elusive, the molecular function of WDR81 in viral infection remains to be fully elucidated. Some information should be provided, and additional experiments are required to further support the authors’ conclusions.

**********

Part II – Major Issues: Key Experiments Required for Acceptance

Please use this section to detail the key new experiments or modifications of existing experiments that should be absolutely required to validate study conclusions.

Generally, there should be no more than 3 such required experiments or major modifications for a "Major Revision" recommendation. If more than 3 experiments are necessary to validate the study conclusions, then you are encouraged to recommend "Reject".

Reviewer #1: Not applicable

Reviewer #2: 1) As outlined above, experiments to determine the nature of the “dead-end compartment” would be very useful in interpreting the nature of the block in reovirus entry. Do these compartments contain lysosomal markers? Accumulation of early endosomal markers?

2) Also as outlined above, experiments examining the location of WDR81 during reovirus entry would also aid interpretation of the potential role for WDR81 in the entry process (is it directly in the endosomal compartments containing virions, or does it exert effects through other means)?

3) A replication time course, examining both reovirus transcript levels over time as well as virus particle production over time, would aid in clarifying the potential role for WDR81 – is it merely delaying entry and protein synthesis, or does it have a role in other processes that facilitate infection?

Reviewer #3: 1. Fig 5. The author speculated that virions or processed ISVP were accumulated in the late endosome (or the dead-end compartment) in WDR81-deficient cells. Co-localization analysis of viral particles and late endosome markers (such as Rab7) is recommended to ensure that the virions were stuck inside the endosome. It is also suggested to analyze the accumulation of virions in the cytoplasm (endosome) of NT and KO cells using electron microscopy.

2. Fig 7. The author tested only two types of late penetrating viruses (reovirus and VSV-expressing Ebola G protein). Can VSV expressing ebolavirus glycoprotein be considered as a late-penetrating virus? References describing the characteristics of this virus should be included. A lot of viruses, including the dengue virus and influenza A virus, use late endosomes for cell entry. Since the title of this paper generalized that WDR81 is involved in cell entry of late penetrating virus, the test using other viruses is recommended.

**********

Part III – Minor Issues: Editorial and Data Presentation Modifications

Please use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity.

Reviewer #1: Specific Comments

Line

51 Consider reading: … establishing infection and to understand…

59f Consider phrasing: … vesicular stomatitis virus Ebolavirus glycoprotein expressing recombinant…

85 to line 103. The text could be slightly condensed.

90 … a number of host factors supporting reovirus replication have been identified…

113 … but fail to initiate further replication. [Throughout manuscript: Since part of the reovirus replication cycle has already been passed when the incoming virus particle reaches late endosomes, it appears slightly odd to speak of ‘infection’ for the further steps from ss(+)RNA transcribing core particles onwards. Rephrasing and clarification of this issue at various later places in the manuscript is suggested.]

147 … Tris-HCl, pH 7.4. [Throughout manuscript when Tris is the basis for a buffer.]

155 … AF488-labeled reovirus virions… Consider referring to the method used to produce them, lines 414ff.

156 … -tosyl-L-lysine chloromethyl ketone (TLCK)- treated chymotrypsin…

201 Omit ‘as previously described [36]’; it is repetitive (see line 197).

233 Omit ‘as previously described’.

254 … deltaWDR81-WDR81 cells… Clarify the meaning.

325 … adsorbed with 103 virions/cell… Is this correct? To how many PFUs does this number of virions correspond?

356 … delta delta CT method… Consider citation of: Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec;25(4):402-8. doi: 10.1006/meth.2001.1262. PMID: 11846609.

518 … is not required for ISVP formation and that the absence of …

564 … due to insufficient expression levels or to less efficient interaction…

607 Fig. 6 should become a Supplementary figure.

626 Consider phrasing: … that expresses the glycoprotein of Ebolavirus, a late penetrating virus, in place of..

635 … not investigated further in this study…

665 … mimics the cell entry pathway of native Ebolavirus… Please provide a ref.

719 When the study of Ortega et al, 2021 (submitted) has been accepted for publication at the time of revision of this manuscript, the reference and text should be fully integrated in this manuscript.

740f Here the Discussion could be improved; the reference to coronaviruses which were not the subject of this study is not an optimal end of Discussion for this manuscript.

912ff References

Consider converting journal names to the accepted abbreviations throughout.

Lines 927-30: omit.

Figure 3, panel A. Try to improve the recognition of the (false) green fluorescence in the right well of the lower line of wells.

Figure 5, panel D. Can the brightness of the green fluorescence be improved?

Figure 6 should be considered to be transferred to Suppl. Mat. Even more than in Fig. 5, the brightness of the green fluorescence should be improved (although it is weaker in absolute terms).

Reviewer #2: 1) The CRISPR-engineered mutation causes a premature stop codon at residue 1338 of 1934, so over 2/3 of the protein is still encoded. Clearly, the protein is not functional to support reovirus infection, but what is known about the structure of the protein that might limit its activity following truncation? Are transmembrane domains missing? More information about the known domain architecture/structure of the protein would be helpful. Additionally, an immunoblot for the protein (I believe a polyclonal antiserum is commercially available?) would help to understand whether a truncated product (dominant negative?) is produced or whether the truncation leads to an unstable/abortive product.

2) Data on virus replication is presented as raw titers, not virus yield. Presenting yield instead of/in addition to virus titers may help interpret the relative impact of WDR81 on the system. Relatedly, the authors claim on line 538 that WDR81 is “required for replication” – clearly, some replication is happening, though not as efficiently as in wild type cells. (As an aside, this is, in itself, interesting – is the virus able to replicate to wild type titers in some small subset of cells that it can gain cytoplasmic access to, or is replication just less efficient or delayed in all cells, leading to the decrease in yield?).

3) Similarly, the experiments with VSV-EBO GP are not conducted to a time when replication plateaus – is replication merely delayed in the WDR81-deficient cells, or will it only infect a subset of the total (clearly the effect in the CTSL-knockouts is more significant, but it is hard to tell where the curve in the WDR81 cells would end up if allowed to progress further).

Reviewer #3: 1. Fig 2. What if the endocytosis inhibitor (such as dynasore) is used? Do the NT cells show similar infectivity to WDR81 deficient cells? What is the balance between cathepsin B and L? Does cathepsin B compensate the function of cathepsin L to induce mu1 cleavage in CTSL deficient cells? In Fig 2A, it was mentioned that the cell viability was checked at 24h and 48h post-infection in the figure legend. However, the analysis at 24h post-infection result is nowhere to be found. Please confirm the results.

2. Figs 2 and 3. In Figs 2G-H, it was revealed that the viral titer in ΔWDR81 cells was decreased in accordance with its infectivity. However, in Figs 3C-D, the reovirus infectivity of WDR81-complemented cells was still decreased, but the viral titer of WDR81-complemented cells was the same as that of NT-empty cells. I am intrigued whether the ΔWDR81 cells inhibit the reovirus infection completely or just delay the replication. Thus, I would suggest multiple step reovirus growth assay to address this. In addition, what is the reason for using human WDR81 instead of murine WDR81? The homology between those two genes is pretty high, however, infectivity in WDR81-complemented cells is still different from that in NT cells, hence it is not ideal complementation unless there is any explanation. Please provide any reasoning regarding this decision.

3. Fig 5. Why is the virus not accumulated in the late endosome in CTSL deficient cells? As mentioned in the manuscript, the virions are not able to be converted to ISVP in the CTSL deficient cells, resulting in the failure of viral penetration. The author should give a discussion on that part.

4. Line 85. .. is a segmented double-stranded RNA (dsRNA) virus..

5. The author identified several genes including WDR81, WDR91, and CTSL that were required for the reovirus infection by CRISPR-Cas9 screening and focused on the role of WDR81 (and CTSL) in reovirus infection. The author also mentioned that WDR81 and its binding partner WDR91 play an important role in endosomal maturation. Thus, the author might want to include the data indicating the importance between WDR81 and WDR91 interaction in reovirus infection if possible.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here on PLOS Biology: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Decision Letter 1

Christopher F Basler, Christiane E Wobus

17 Feb 2022

Dear Dr. Danthi,

Thank you very much for submitting the revised version of your manuscript "A CRISPR-Cas9 screen reveals a role for WD repeat-containing protein 81 (WDR81) in the entry of late penetrating viruses" for consideration at PLOS Pathogens. Your response to reviewers comments and revised manuscript was reviewed by members of the editorial board. We appreciate the detailed and thoughtful response and inclusion of new experimental data in Figures 7 and 8. However, Fig. 7 and 8 provide representative images of immunofluorescence images but lacks quantification across different experiments to support statements in the text. For example: What is the proportion of virions colocalized with EEA1 in the various conditions in Fig. 7? In Figure 8, what proportion of virus was colocalized with Rab7 and Lamp1 in the different conditions? 

We are likely to accept this manuscript for publication provided that you modify the manuscript accordingly by adding quantification to Figures 7 and 8 and making any necessary edits to the manuscript.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Christiane E. Wobus

Associate Editor

PLOS Pathogens

Christopher Basler

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************

Reviewer Comments (if any, and for reference):

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Decision Letter 2

Christopher F Basler, Christiane E Wobus

25 Feb 2022

Dear Dr. Danthi,

We are pleased to inform you that your manuscript 'A CRISPR-Cas9 screen reveals a role for WD repeat-containing protein 81 (WDR81) in the entry of late penetrating viruses' has been provisionally accepted for publication in PLOS Pathogens.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Christiane E. Wobus

Associate Editor

PLOS Pathogens

Christopher Basler

Section Editor

PLOS Pathogens

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

***********************************************************

Reviewer Comments (if any, and for reference):

Acceptance letter

Christopher F Basler, Christiane E Wobus

9 Mar 2022

Dear Dr. Danthi,

We are delighted to inform you that your manuscript, "A CRISPR-Cas9 screen reveals a role for WD repeat-containing protein 81 (WDR81) in the entry of late penetrating viruses," has been formally accepted for publication in PLOS Pathogens.

We have now passed your article onto the PLOS Production Department who will complete the rest of the pre-publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Pearls, Reviews, Opinions, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript, if you opted to have an early version of your article, will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Pathogens.

Best regards,

Kasturi Haldar

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0001-5065-158X

Michael Malim

Editor-in-Chief

PLOS Pathogens

orcid.org/0000-0002-7699-2064

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Infection of WDR81-deficient cells by T3DCD (AF488) ISVPs.

    (A) Protein compositions. Unlabeled and AF488-labeled T3DCD ISVPs were analyzed by SDS-PAGE. The gel was Coomassie brilliant blue stained (left side panel) and scanned for AF488 fluorescence (right side panel). The migration of capsid proteins is indicated on the left. μ1δ resolves as δ [74] (n = 4 biological replicates; results for 1 representative experiment are shown). (B) Size distribution profiles. Unlabeled and AF488-labeled T3DCD ISVPs were analyzed by dynamic light scattering (n = 4 biological replicates; results from 1 representative experiment are shown). (C) Specific infectivity. The titers of unlabeled and AF488-labeled T3DCD ISVPs (2×1012 particles/ml) were determined by plaque assay. Horizontal bars indicate the means (n = 4 biological replicates). (D) Localization within an infected cell. NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD (AF488) at 10,000 ISVPs/cell. At 2 h post infection (hpi), the infected monolayers were fixed, stained with DAPI, mounted, and imaged by confocal microscopy. The images were obtained using a X63 oil-immersion objective and processed using ImageJ software [42]. The DAPI signal is false colored in blue, and the AF488 signal is false colored in green. The inset boxes in the ‘Merge’ column are expanded in the ‘Merge (zoom)’ column. The scale bars represent 20 μm (n = 3 biological replicates; results from 1 representative experiment are shown).

    (TIF)

    S2 Fig. Quantification of colocalization between T3DCD (AF488) virions and EEA1, Rab7, or LAMP1 in WDR81-deficient cells.

    (A-C) NT, ΔCTSL, and ΔWDR81 cells were infected with T3DCD (AF488) at 10,000 virions/cell. At 2 h post infection (hpi), the infected monolayers were fixed, stained with an anti-EEA1, anti-Rab7, or anti-LAMP1 primary antibody and with DAPI, mounted, and imaged by confocal microscopy. The images were obtained using a X63 oil-immersion objective and processed using ImageJ software [42]. Pearson’s correlation coefficient between AF488 and EEA1 (A), Rab7 (B), or LAMP1 (C) was calculated using Just Another Colocalization Plugin (JACoP) [43]. Horizontal bars indicate the means; **, P ≤ 0.005 (n = 3 biological replicates).

    (TIF)

    S1 Data. Numerical values that were used to generate Tables and Figures in the manuscript are included. Each tab represents data for a different figure.

    (XLSX)

    Attachment

    Submitted filename: CRISPR response to reviewer final.docx

    Attachment

    Submitted filename: Dear PLoS Pathogens Editors.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS Pathogens are provided here courtesy of PLOS

    RESOURCES